{"content":"<li class=\"n-box-item date-title\" data-end=\"1518584399\" data-start=\"1518498000\" data-txt=\"Monday, December 23, 2019\">Tuesday, February 13, 2018</li><li class=\"n-box-item sa-box-item\" data-id=\"3330806\" data-ts=\"1518569219\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RARX\" target=\"_blank\">RARX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330806-ra-pharmaceuticalsminus-2_1-plans-50m-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ra Pharmaceuticals -2.1% as it plans $50M offering</a></h4><ul>   <li>Ra Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/RARX' title='Ra Pharmaceuticals'>RARX</a>) is <font color='red'>2.1% lower</font> postmarket after word that it's <a href=\"https://seekingalpha.com/pr/17074087-ra-pharmaceuticals-announces-proposed-public-offering-common-stock\" target=\"_blank\">pursuing a $50M stock offering</a>.</li>    <li>Net proceeds will go to fund its phase 2 trial for RA101495 for gMG, among other pipeline programs and general purposes.</li>    <li>Underwriters are expected to get a 30-day option to buy up to $7.5M in additional shares.</li>    <li>Joint book-runners are Credit Suisse, Jefferies, and BMO Capital Markets.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3330806\" data-linked=\"Ra Pharmaceuticals -2.1% as it plans $50M offering\" data-tweet=\"$RARX - Ra Pharmaceuticals -2.1% as it plans $50M offering https://seekingalpha.com/news/3330806-ra-pharmaceuticalsminus-2_1-plans-50m-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3330806-ra-pharmaceuticalsminus-2_1-plans-50m-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:46 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330805\" data-ts=\"1518567704\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PSX\" target=\"_blank\">PSX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330805-phillips-66-to-repurchase-35m-shares-from-berkshire-hathaway\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Phillips 66 to repurchase 35M shares from Berkshire Hathaway</a></h4><ul>     <li>Phillips 66 (NYSE:<a href='https://seekingalpha.com/symbol/PSX' title='Phillips 66'>PSX</a>) <font color='green'>+1.6%</font> after-hours following news it agrees to <a href=\"https://seekingalpha.com/pr/17074104-phillips-66-berkshire-hathaway-announce-share-repurchase-agreement\" target=\"_blank\">repurchase 35M of its shares</a> from a Berkshire Hathaway (<a href='https://seekingalpha.com/symbol/BRK.A' title='Berkshire Hathaway A'>BRK.A</a>, <a href='https://seekingalpha.com/symbol/BRK.B' title='Berkshire Hathaway B'>BRK.B</a>) subsidiary for $93.725/share, or ~$3.3B.</li>     <li>BRK's Warren Buffett says the sale was <a href=\"https://www.reuters.com/article/brief-phillips-66-and-berkshire-hathaway/brief-phillips-66-and-berkshire-hathaway-announce-share-repurchase-agreement-idUSASB0C5KK\" target=\"_blank\">solely motivated</a> by the \"desire to eliminate regulatory requirements\" associated with ownership levels above 10%, and &ldquo;we remain one of [PSX's] largest shareholders and plan to continue to hold stock for the long term.\"</li><li>When the deal closes, PSX will have 466.5M shares outstanding, with Berkshire owning 45.7M shares.</li></ul><div class=\"tiny-share-widget\" data-id=\"3330805\" data-linked=\"Phillips 66 to repurchase 35M shares from Berkshire Hathaway\" data-tweet=\"$PSX $PSX $BRK.A - Phillips 66 to repurchase 35M shares from Berkshire Hathaway https://seekingalpha.com/news/3330805-phillips-66-to-repurchase-35m-shares-from-berkshire-hathaway?source=tweet\" data-url=\"https://seekingalpha.com/news/3330805-phillips-66-to-repurchase-35m-shares-from-berkshire-hathaway\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>82&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330803\" data-ts=\"1518567064\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NMM\" target=\"_blank\">NMM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330803-navios-maritime-partners-to-launch-35m-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Navios Maritime Partners to launch $35M offering</a></h4><ul>     <li>Navios Maritime Partners (NYSE:<a href='https://seekingalpha.com/symbol/NMM' title='Navios Maritime Partners L.P.'>NMM</a>) <font color='red'>-11.6%</font> after-hours as it announces a <a href=\"https://seekingalpha.com/pr/17073982-navios-maritime-partners-l-p-announces-public-offering-common-units\" target=\"_blank\">public offering</a> of as much as $35M of common units.</li><li>NMM says it plans to use the proceeds for general working capital purposes, including vessel acquisitions.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3330803\" data-linked=\"Navios Maritime Partners to launch $35M offering\" data-tweet=\"$NMM - Navios Maritime Partners to launch $35M offering https://seekingalpha.com/news/3330803-navios-maritime-partners-to-launch-35m-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3330803-navios-maritime-partners-to-launch-35m-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>67&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330800\" data-ts=\"1518565130\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWTR\" target=\"_blank\">TWTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330800-ceo-twitter-still-too-hard-likes-company-independence\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CEO: Twitter still too hard; he likes company &#39;independence&#39;</a></h4><ul>   <li>Among hints about Twitter (NYSE:<a href='https://seekingalpha.com/symbol/TWTR' title='Twitter, Inc.'>TWTR</a>) from today's Goldman Sachs investor conference, CEO Jack Dorsey notes the company and its product are <a href=\"https://www.cnbc.com/2018/02/13/jack-dorsey-tells-investors-twitter-is-still-too-hard-to-use.html?__source=yahoo|finance|headline|story|&amp;par=yahoo&amp;yptr=yahoo\" target=\"_blank\">still too hard</a> for users -- and, just as important, for advertisers.</li>    <li>One-third of the 2M new people who come every day come with expectations of what (Twitter) should be, then get disappointed when they can't find what they want ... It's a lot of work right now.</li>    <li>Shares <font color='green'>rose 8.1%</font> today, continuing a run since Thursday saw the company's <a href=\"https://seekingalpha.com/news/3329429-twitter-soars-turning-profit\" target=\"_blank\">first quarterly profit</a>.</li>    <li>The company's working on a more personalized experience for each user, Dorsey says, as well as easier ways to express themselves than just text: \"We got stuck in the age of typing.\" Video is the fastest-growing content, he says.</li>    <li>Advertisers are looking for an easier way, too: \"People are saying, 'I need this to be easier, I need to be able to measure this and prove that it works' ... They're asking for a lot more simplicity.\"</li>    <li>Meanwhile, he also seemed to wave off a company sale, saying &ldquo;I&rsquo;ve always felt there&rsquo;s a <a href=\"http://variety.com/2018/digital/news/twitter-ceo-jack-dorsey-acquisition-independence-1202697801/\" target=\"_blank\">lot of strength to our independence</a>\" when asked if he saw advantages to being part of a bigger company.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3330800\" data-linked=\"CEO: Twitter still too hard; he likes company &#39;independence&#39;\" data-tweet=\"$TWTR - CEO: Twitter still too hard; he likes company &#39;independence&#39; https://seekingalpha.com/news/3330800-ceo-twitter-still-too-hard-likes-company-independence?source=tweet\" data-url=\"https://seekingalpha.com/news/3330800-ceo-twitter-still-too-hard-likes-company-independence\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330791\" data-ts=\"1518561342\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FOSL\" target=\"_blank\">FOSL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330791-after-hours-gainers-losers-2-13-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers (2/13/2018)</a></h4><ul>     <li><b>Top gainers:</b> <a href='https://seekingalpha.com/symbol/FOSL' title='Fossil, Inc.'>FOSL</a> <font color='green'>+55.9%</font>. <a href='https://seekingalpha.com/symbol/CMG' title='Chipotle Mexican Grill, Inc.'>CMG</a> <font color='green'>+12.0%</font>. <a href='https://seekingalpha.com/symbol/CCS' title='Century Communities, Inc.'>CCS</a> <font color='green'>+10.2%</font>. <a href='https://seekingalpha.com/symbol/FANG' title='Diamondback Energy'>FANG</a> <font color='green'>+5.5%</font>. <a href='https://seekingalpha.com/symbol/TWLO' title='Twilio'>TWLO</a>&nbsp;<font color='green'>+5.5%</font>.</li><li><b>Top losers:</b> <a href='https://seekingalpha.com/symbol/TTPH' title='Tetraphase Pharmaceuticals'>TTPH</a> <font color='red'>-59.5%</font>. <a href='https://seekingalpha.com/symbol/AVDL' title='Avadel Pharmaceuticals plc'>AVDL</a> <font color='red'>-13.2%</font>. <a href='https://seekingalpha.com/symbol/ECOM' title='ChannelAdvisor Corp'>ECOM</a> <font color='red'>-12.8%</font>. <a href='https://seekingalpha.com/symbol/NBIX' title='Neurocrine Biosciences, Inc.'>NBIX</a> <font color='red'>-5.5%</font>. <a href='https://seekingalpha.com/symbol/ACTG' title='Acacia Research Corporation'>ACTG</a> <font color='red'>-4.1%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3330791\" data-linked=\"After Hours Gainers / Losers (2/13/2018)\" data-tweet=\"$FOSL $FOSL $CMG - After Hours Gainers / Losers (2/13/2018) https://seekingalpha.com/news/3330791-after-hours-gainers-losers-2-13-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3330791-after-hours-gainers-losers-2-13-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330776\" data-ts=\"1518559303\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TTPH\" target=\"_blank\">TTPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330776-tetraphase-pharmas-eravacycline-fails-to-match-ertapenem-in-late-stage-cuti-study-shares-down\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tetraphase Pharma&#39;s eravacycline fails to match ertapenem in late-stage cUTI study; shares down 57% after hours</a></h4><ul><li>Tetraphase Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/TTPH' title='Tetraphase Pharmaceuticals'>TTPH</a>) craters&nbsp;<font color='red'>57%</font>&nbsp;after hours on robust volume in response to its <a href=\"https://seekingalpha.com/pr/17073876-tetraphase-announces-top-line-results-ignite3-phase-3-clinical-trial-eravacycline-complicated\" target=\"_blank\">announcement </a>that lead candidate IV eravacycline failed to demonstrate non-inferiority (no worse than) to ertapenem in a Phase 3 clinical trial in patients with complicated urinary tract infections (cUTI).</li><li>The study, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03032510?intr=eravacycline&amp;phase=2&amp;rank=4\" target=\"_blank\">IGNITE3</a>, did not achieve the co-primary endpoints of responder rate at the end of treatment and test-of-cure visit.</li><li>CEO Guy Macdonald says, &ldquo;We are surprised and obviously very disappointed that the IGNITE3 trial did not achieve its co-primary endpoints and are fully analyzing the data to understand this outcome. Independent of this outcome, we continue to move forward with our registration strategy for eravacycline in complicated intra-abdominal infections (cIAI).&nbsp; We currently have an NDA under review with the FDA as well as an MAA under review by the EMA in&nbsp;Europe, which are based on the positive outcomes demonstrating high cure rates and favorable tolerability in the IGNITE1 and IGNITE4 phase 3 clinical trials of IV eravacycline in cIAI. We are actively preparing for the commercialization of eravacycline as a treatment in cIAI in both the&nbsp;U.S&nbsp;and in&nbsp;Europe, assuming regulatory approvals.&rdquo;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3235811-late-stage-study-commences-evaluating-tetraphases-lead-candidate-eravacycline-cuti\" target=\"_blank\">Late-stage study commences evaluating Tetraphase's lead candidate eravacycline in cUTI</a> (Jan. 18, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3330776\" data-linked=\"Tetraphase Pharma&#39;s eravacycline fails to match ertapenem in late-stage cUTI study; shares down 57% after hours\" data-tweet=\"$TTPH - Tetraphase Pharma&#39;s eravacycline fails to match ertapenem in late-stage cUTI study; shares down 57% after hours https://seekingalpha.com/news/3330776-tetraphase-pharmas-eravacycline-fails-to-match-ertapenem-in-late-stage-cuti-study-shares-down?source=tweet\" data-url=\"https://seekingalpha.com/news/3330776-tetraphase-pharmas-eravacycline-fails-to-match-ertapenem-in-late-stage-cuti-study-shares-down\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330763\" data-ts=\"1518558724\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIDU\" target=\"_blank\">BIDU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330763-baiduplus-4_7-after-q4-eps-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Baidu +4.7% after Q4 EPS beat</a></h4><ul><li>        Baidu (NASDAQ:<a href='https://seekingalpha.com/symbol/BIDU' title='Baidu, Inc.'>BIDU</a>) shares are&nbsp;<font color='green'>up 4.7%</font>&nbsp;aftermarket following Q4 results that beat EPS estimates and narrowly missed on revenue.&nbsp;</li><li>        Q1 guidance: Revenue, $3.05B to $3.22B (consensus: $3.28B) using the new ASC 606 accounting standard.</li><li>               Key metrics: Revenue per online marketing customer, $6.8B (+25% Y/Y); TAC as a component of cost of revenue, 10.7% (compared to 14.5% Y/Y); bandwidth costs as a component of cost of revenues, 5.9% (was: 6.8%); content costs as a component of cost of revenues, 15.9% (was: 14.1%).&nbsp;</li><li>               Earnings call is scheduled for 8 PM Eastern Time with a webcast available <a href=\"http://ir.baidu.com/phoenix.zhtml?c=188488&amp;p=irol-irhome\" target=\"_blank\">here</a>. &nbsp;&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/17073997-baidu-announces-fourth-quarter-fiscal-year-2017-results\" target=\"_blank\">Press conference</a>&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3330732-baidu-beats-0_19-misses-revenue\" target=\"_blank\">Baidu beats by $0.19, misses on revenue</a> (Feb. 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3330763\" data-linked=\"Baidu +4.7% after Q4 EPS beat\" data-tweet=\"$BIDU - Baidu +4.7% after Q4 EPS beat https://seekingalpha.com/news/3330763-baiduplus-4_7-after-q4-eps-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3330763-baiduplus-4_7-after-q4-eps-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:52 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330757\" data-ts=\"1518558172\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMG\" target=\"_blank\">CMG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330757-chipotle-pops-after-nabbing-taco-bell-ceo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chipotle pops after nabbing Taco Bell CEO</a></h4><ul>         <li>Chipotle (NYSE:<a href='https://seekingalpha.com/symbol/CMG' title='Chipotle Mexican Grill, Inc.'>CMG</a>) officially&nbsp;announces that&nbsp;Brian Niccol&nbsp;has been hired as chief executive officer and will be added to the company's board.</li><li>The appointments become effective on March 5.</li><li>\"I will also focus on dialing up Chipotle's cultural relevance through innovation in menu and digital communications. This will attract customers, return the brand to growth, deliver value for shareholders and create opportunities for employees,\" says Niccol.</li><li>Shares of Chipotle have jetted&nbsp;<font color='green'>up 11.81%</font>&nbsp;in AH trading to $281.01.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3330738-taco-bell-ceo-heads-chipotle\" target=\"_blank\">Taco Bell CEO heads to Chipotle</a> (Feb. 13)</li>     <li>Source: <a href=\"https://seekingalpha.com/pr/17074014-chipotle-names-brian-niccol-chief-executive-officer\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3330757\" data-linked=\"Chipotle pops after nabbing Taco Bell CEO\" data-tweet=\"$CMG - Chipotle pops after nabbing Taco Bell CEO https://seekingalpha.com/news/3330757-chipotle-pops-after-nabbing-taco-bell-ceo?source=tweet\" data-url=\"https://seekingalpha.com/news/3330757-chipotle-pops-after-nabbing-taco-bell-ceo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>41&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330737\" data-ts=\"1518557558\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWLO\" target=\"_blank\">TWLO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330737-twilioplus-5_7-after-q4-beats-mixed-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Twilio +5.7% after Q4 beats, mixed guidance</a></h4><ul><li>        Twilio (NYSE:<a href='https://seekingalpha.com/symbol/TWLO' title='Twilio'>TWLO</a>) shares are&nbsp;<font color='green'>up 5.7%</font>&nbsp;aftermarket following Q4 results that beat EPS and revenue estimates.</li><li>               Mixed Q1 guidance: Revenue, $115M to $117M (consensus: $108.17M); EPS, -$0.07 to -$0.06 (consensus: -$0.05).&nbsp;</li><li>               Mixed FY18 guidance: Revenue, $506M to $514M (consensus: $481.39M); EPS, -$0.14 to -$0.10 (consensus: - $0.09).&nbsp;</li><li>               Leadership change: CFO Lee Kirkpatrick announced plans to leave the company but will remain in the role until his successor is found and has moved into the role. The search for the new CFO is expected to complete by year&rsquo;s end.&nbsp;</li><li>               Earnings call is scheduled for 5 PM Eastern Time with a webcast available <a href=\"https://investors.twilio.com/home/default.aspx\" target=\"_blank\">here</a>.&nbsp;</li><li>           <a href=\"https://seekingalpha.com/pr/17073954-twilio-announces-fourth-quarter-full-year-2017-results\" target=\"_blank\">Press release</a>&nbsp; </li><li>Previously: <a href=\"https://seekingalpha.com/news/3330724-twilio-beats-0_03-beats-revenue\" target=\"_blank\">Twilio beats by $0.03, beats on revenue</a> (Feb. 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3330737\" data-linked=\"Twilio +5.7% after Q4 beats, mixed guidance\" data-tweet=\"$TWLO - Twilio +5.7% after Q4 beats, mixed guidance https://seekingalpha.com/news/3330737-twilioplus-5_7-after-q4-beats-mixed-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3330737-twilioplus-5_7-after-q4-beats-mixed-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330732\" data-ts=\"1518557494\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIDU\" target=\"_blank\">BIDU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330732-baidu-beats-0_19-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Baidu beats by $0.19, misses on revenue</a></h4><ul><li>Baidu (NASDAQ:<a href='https://seekingalpha.com/symbol/BIDU' title='Baidu, Inc.'>BIDU</a>): Q4 EPS of $2.29 <font color='green'>beats by $0.19</font>.</li><li>Revenue of $3.62B (+25.7% Y/Y) <font color='red'>misses by $20M</font>.</li><li>Shares <font color='green'>+2.25%</font>.</li><li><a href='https://seekingalpha.com/pr/17073997-baidu-announces-fourth-quarter-fiscal-year-2017-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3330732\" data-linked=\"Baidu beats by $0.19, misses on revenue\" data-tweet=\"$BIDU - Baidu beats by $0.19, misses on revenue https://seekingalpha.com/news/3330732-baidu-beats-0_19-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3330732-baidu-beats-0_19-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330729\" data-ts=\"1518557378\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CNO\" target=\"_blank\">CNO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330729-cno-financial-beats-0_10-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CNO Financial beats by $0.10, beats on revenue</a></h4><ul><li>CNO Financial (NYSE:<a href='https://seekingalpha.com/symbol/CNO' title='CNO Financial Group, Inc.'>CNO</a>): Q4 EPS of $0.51 <font color='green'>beats by $0.10</font>.</li><li>Revenue of $1.09B (+9.0% Y/Y) <font color='green'>beats by $80M</font>.</li><li>Shares <font color='green'>+2.6%</font>.</li><li><a href='https://seekingalpha.com/pr/17073958-cno-financial-group-reports-fourth-quarter-full-year-2017-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3330729\" data-linked=\"CNO Financial beats by $0.10, beats on revenue\" data-tweet=\"$CNO - CNO Financial beats by $0.10, beats on revenue https://seekingalpha.com/news/3330729-cno-financial-beats-0_10-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3330729-cno-financial-beats-0_10-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:29 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330725\" data-ts=\"1518557270\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FANG\" target=\"_blank\">FANG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330725-diamondback-energyplus-4-after-strong-q4-results-initiates-dividend\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Diamondback Energy +4% after strong Q4 results; initiates dividend</a></h4><ul>     <li>Diamondback Energy (NASDAQ:<a href='https://seekingalpha.com/symbol/FANG' title='Diamondback Energy'>FANG</a>)&nbsp;<font color='green'>+4.4%</font> after-hours as it reports better than expected <a href=\"https://seekingalpha.com/news/3330678-diamondback-energy-beats-0_05-beats-revenue\" target=\"_blank\">Q4 earnings</a> with revenues more than doubling Y/Y to $399M, also exceeding expectations.</li>     <li>FANG says Q4 production rose 9% Q/Q and 79% Y/Y to 92.9K boe/day, and FY 2017 output of 79.2K boe/day jumped 84% Y/Y within operating cash flow; proved reserves at year-end 2017 totaled 335.4M boe, up 63% Y/Y.</li>     <li>For FY 2018, FANG expects production of 108M-116M boe/day and plans to complete 170 -190 gross operated horizontal wells from a 10-12 rig program; planned 2018 capex is $1.3B-$1.5B.</li>     <li>FANG also says it is initiating an annual cash dividend of $0.50/share beginning with Q1.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3330725\" data-linked=\"Diamondback Energy +4% after strong Q4 results; initiates dividend\" data-tweet=\"$FANG - Diamondback Energy +4% after strong Q4 results; initiates dividend https://seekingalpha.com/news/3330725-diamondback-energyplus-4-after-strong-q4-results-initiates-dividend?source=tweet\" data-url=\"https://seekingalpha.com/news/3330725-diamondback-energyplus-4-after-strong-q4-results-initiates-dividend\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330724\" data-ts=\"1518557268\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWLO\" target=\"_blank\">TWLO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330724-twilio-beats-0_03-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Twilio beats by $0.03, beats on revenue</a></h4><ul><li>Twilio (NYSE:<a href='https://seekingalpha.com/symbol/TWLO' title='Twilio'>TWLO</a>): Q4 EPS of -$0.03 <font color='green'>beats by $0.03</font>.</li><li>Revenue of $115.2M (+40.6% Y/Y) <font color='green'>beats by $11.49M</font>.</li><li>Shares <font color='green'>+5.1%</font>.</li><li><a href='https://seekingalpha.com/pr/17073954-twilio-announces-fourth-quarter-full-year-2017-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3330724\" data-linked=\"Twilio beats by $0.03, beats on revenue\" data-tweet=\"$TWLO - Twilio beats by $0.03, beats on revenue https://seekingalpha.com/news/3330724-twilio-beats-0_03-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3330724-twilio-beats-0_03-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330717\" data-ts=\"1518556939\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FOSL\" target=\"_blank\">FOSL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330717-fossil-skyrockets-after-comp-sales-stunner\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fossil skyrockets after comp sales stunner</a></h4><ul>     <li>Fossil (NASDAQ:<a href='https://seekingalpha.com/symbol/FOSL' title='Fossil, Inc.'>FOSL</a>) reports comparable sales rose 2% in Q4 to sail the past the consensus estimate for a 6% drop. The magnitude of the sales beat isn't seen often for a company the size of Fossil.</li>     <li>Positive comparable sales growth in the watch category helped Fossil offset a negative comp in both the leathers and jewelry categories.  Positive comparable sales in the Americas and Europe offset a drop in Asia.</li><li>Gross margin came in at 48.7% of sales for the quarter vs. 51.0% a year ago.</li>     <li>\"In the year ahead, we expect to be a smaller yet more profitable company that is on a solid path for the future,\" says Fossil CEO Kosta Kartsotis.</li><li>FOSL is&nbsp;<font color='green'>up 50%</font>&nbsp;in AH to $13.55 after jumping 7.7% before the bell.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3330694-fossil-beats-0_27-beats-revenue\" target=\"_blank\">Fossil beats by $0.27, beats on revenue</a> (Feb. 13)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3330717\" data-linked=\"Fossil skyrockets after comp sales stunner\" data-tweet=\"$FOSL - Fossil skyrockets after comp sales stunner https://seekingalpha.com/news/3330717-fossil-skyrockets-after-comp-sales-stunner?source=tweet\" data-url=\"https://seekingalpha.com/news/3330717-fossil-skyrockets-after-comp-sales-stunner\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330696\" data-ts=\"1518556347\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ESNC\" target=\"_blank\">ESNC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330696-ensync-beats-0_02-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EnSync beats by $0.02, beats on revenue</a></h4><ul><li>EnSync (NYSEMKT:<a href='https://seekingalpha.com/symbol/ESNC' title='EnSync, Inc.'>ESNC</a>): Q2 EPS of -$0.05 <font color='green'>beats by $0.02</font>.</li><li>Revenue of $4.85M (+178.7% Y/Y) <font color='green'>beats by $1.88M</font>.</li><li>Shares <font color='green'>+7.76%</font>.</li><li><a href='https://seekingalpha.com/pr/17073888-ensync-energy-reports-second-quarter-fiscal-year-2018-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3330696\" data-linked=\"EnSync beats by $0.02, beats on revenue\" data-tweet=\"$ESNC - EnSync beats by $0.02, beats on revenue https://seekingalpha.com/news/3330696-ensync-beats-0_02-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3330696-ensync-beats-0_02-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330694\" data-ts=\"1518556322\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FOSL\" target=\"_blank\">FOSL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330694-fossil-beats-0_27-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fossil beats by $0.27, beats on revenue</a></h4><ul><li>Fossil (NASDAQ:<a href='https://seekingalpha.com/symbol/FOSL' title='Fossil, Inc.'>FOSL</a>): Q4 EPS of $0.67 <font color='green'>beats by $0.27</font>.</li><li>Revenue of $920.8M (-4.0% Y/Y) <font color='green'>beats by $31.24M</font>.</li><li>Shares <font color='green'>+38.72%</font>.</li><li><a href='https://seekingalpha.com/pr/17073917-fossil-group-inc-reports-fourth-quarter-fiscal-year-2017-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3330694\" data-linked=\"Fossil beats by $0.27, beats on revenue\" data-tweet=\"$FOSL - Fossil beats by $0.27, beats on revenue https://seekingalpha.com/news/3330694-fossil-beats-0_27-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3330694-fossil-beats-0_27-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330691\" data-ts=\"1518556150\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVDA\" target=\"_blank\">NVDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330691-nvidiaplus-2-after-cfos-comments-tech-conference\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nvidia +2% after CFO&#39;s comments at tech conference</a></h4><ul><li>        Nvidia (NASDAQ:<a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a>) shares closed today&nbsp;<font color='green'>up 2%</font>&nbsp;following CFO Colette Kress&rsquo; presentation at the Goldman Sachs Technology &amp; Internet Conference.</li><li>               Kress said Nvidia&rsquo;s data center business continues to benefit from AI growth and management is focused on a wide set of customers and uses rather than specific applications.&nbsp;</li><li>               Kress noted that cryptocurrency demand is expected to continue but will likely remain volatile.&nbsp;</li><li>               The CFO also said Nvidia is well positioned to benefit from the adoption of self-driving cars.&nbsp;</li><li>               Source: Bloomberg First Word. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3330691\" data-linked=\"Nvidia +2% after CFO&#39;s comments at tech conference\" data-tweet=\"$NVDA - Nvidia +2% after CFO&#39;s comments at tech conference https://seekingalpha.com/news/3330691-nvidiaplus-2-after-cfos-comments-tech-conference?source=tweet\" data-url=\"https://seekingalpha.com/news/3330691-nvidiaplus-2-after-cfos-comments-tech-conference\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>68&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330685\" data-ts=\"1518556014\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SAH\" target=\"_blank\">SAH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330685-auto-dealer-stocks-cool-off-after-hot-streak\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Auto dealer stocks cool off after hot streak</a></h4><ul><li>Auto dealer stocks continue to cool off after hitting record highs in the last part of January on tax benefit optimism.</li><li>Notable decliners today included Sonic Automotive (<a href='https://seekingalpha.com/symbol/SAH' title='Sonic Automotive Inc.'>SAH</a> <font color='red'>-3.7%</font>), CarMax (<a href='https://seekingalpha.com/symbol/KMX' title='CarMax Group'>KMX</a> <font color='red'>-3.5%</font>), Group 1 Automotive (<a href='https://seekingalpha.com/symbol/GPI' title='Group 1 Automotive Inc.'>GPI</a> <font color='red'>-3.6%</font>), AutoNation (<a href='https://seekingalpha.com/symbol/AN' title='AutoNation Inc'>AN</a> <font color='red'>-2.2%</font>), Penske Automotive Group (<a href='https://seekingalpha.com/symbol/PAG' title='Penske Automotive Group, Inc.'>PAG</a> <font color='red'>-2.3%</font>) and Asbury Automotive Group (<a href='https://seekingalpha.com/symbol/ABG' title='Asbury Automotive Group, Inc.'>ABG</a> <font color='red'>-1.8%</font>).</li><li>Most of the sector is still up on a YTD basis, with Sonic Automotive topping the group.</li></ul><div class=\"tiny-share-widget\" data-id=\"3330685\" data-linked=\"Auto dealer stocks cool off after hot streak\" data-tweet=\"$SAH $SAH $KMX - Auto dealer stocks cool off after hot streak https://seekingalpha.com/news/3330685-auto-dealer-stocks-cool-off-after-hot-streak?source=tweet\" data-url=\"https://seekingalpha.com/news/3330685-auto-dealer-stocks-cool-off-after-hot-streak\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330682\" data-ts=\"1518555968\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DYNT\" target=\"_blank\">DYNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330682-dynatronics-misses-0_24-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dynatronics misses by $0.24, beats on revenue</a></h4><ul><li>Dynatronics (NASDAQ:<a href='https://seekingalpha.com/symbol/DYNT' title='Dynatronics Corporation'>DYNT</a>): Q2 EPS of -$0.23 <font color='red'>misses by $0.24</font>.</li><li>Revenue of $18.1M (+107.8% Y/Y) <font color='green'>beats by $0.33M</font>.</li><li>Shares <font color='green'>+6.35%</font>.</li><li><a href='https://seekingalpha.com/pr/17073865-dynatronics-announces-107_5-percent-increase-top-line-sales-fiscal-2018-second-quarter'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3330682\" data-linked=\"Dynatronics misses by $0.24, beats on revenue\" data-tweet=\"$DYNT - Dynatronics misses by $0.24, beats on revenue https://seekingalpha.com/news/3330682-dynatronics-misses-0_24-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3330682-dynatronics-misses-0_24-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330672\" data-ts=\"1518555573\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NINE\" target=\"_blank\">NINE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330672-nine-energy-services-started-buy-rating-goldman\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nine Energy Services started with Buy rating at Goldman</a></h4><ul><li>Nine Energy Services (<a href='https://seekingalpha.com/symbol/NINE' title='Nine Energy Service, Inc.'>NINE</a> <font color='green'>+2.1%</font>) has shed nearly 10% since launching its IPO just <a href=\"https://seekingalpha.com/news/3323777-nine-energy-service-prices-ipo-top-range\" target=\"_blank\">a month ago</a>, but Goldman Sachs thinks the stock could gain as much as 70%, as the firm initiates coverage with a <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/18/02/11186682/goldman-sachs-highlights-nine-energys-significant-margi\" target=\"_blank\">Buy rating</a> and $39.50 price target.</li><li>Nine offers investors exposure to the \"rising complexity\" of U.S. shale wells but with a less capital intensive business model, the firm says.</li><li>Nine's cementing and coiled tubing businesses are key advantages and benefit from longer lateral wells, and its wireline and completion tools units benefit from higher frac storage count, which Goldman expects to increase by 33% in 2018 and 13% in 2019.</li></ul><div class=\"tiny-share-widget\" data-id=\"3330672\" data-linked=\"Nine Energy Services started with Buy rating at Goldman\" data-tweet=\"$NINE - Nine Energy Services started with Buy rating at Goldman https://seekingalpha.com/news/3330672-nine-energy-services-started-buy-rating-goldman?source=tweet\" data-url=\"https://seekingalpha.com/news/3330672-nine-energy-services-started-buy-rating-goldman\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330670\" data-ts=\"1518555192\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SQNS\" target=\"_blank\">SQNS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330670-sequansminus-3_9-after-revenues-slip-19\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sequans -3.9% after revenues slip 19%</a></h4><ul>   <li>Sequans Communications (NYSE:<a href='https://seekingalpha.com/symbol/SQNS' title='Sequans Communications'>SQNS</a>) is <font color='red'>3.9% lower</font> today after <a href=\"https://seekingalpha.com/news/3330405-sequans-communications-eps-line-misses-revenue\" target=\"_blank\">Q4 earnings</a> came in mostly in line, and revenues fell by nearly 20%.</li>    <li>Sales were also sequentially flat. Gross margin rose Y/Y to 41.7% from 38.2%, with an increase in the proportion of module sales Q/Q, and proportionally higher other revenue Y/Y.</li>    <li>\"We expect strong acceleration of IoT growth in 2018, based on a full year of Cat 1 revenue from both the United States and Japan, as well as the initial Cat M1/NB1 ramp from U.S. design wins already in hand,\" says CEO Georges Karam. \"We expect gradual improvement in our broadband business beginning in the second quarter.\"</li>    <li>Revenue breakout: Product, $8.685M (down 27.3%); Other, $2.6M (up 31.2%).</li>    <li>Cash, equivalents and short-term deposit was $3.3M at Dec. 31, compared to $13.3M as of Sept. 31.</li>    <li>For a seasonally weak Q1, it's guiding to revenue of $10.5M-$12M (vs. consensus for $11.39M) and adjusted gross margin above 40%, along with EPADS of -$0.07 to -$0.08 (vs. consensus for -$0.08).</li>    <li><a href=\"https://seekingalpha.com/article/4146163-sequans-communications-2017-q4-results-earnings-call-slides\" target=\"_blank\">Earnings call slides</a></li>    <li><a href=\"https://seekingalpha.com/article/4146233-sequans-communications-sqns-ceo-georges-karam-q4-2017-results-earnings-call-transcript\" target=\"_blank\">Call transcript</a></li>    <li><a href=\"https://seekingalpha.com/pr/17072688-sequans-communications-announces-fourth-quarter-2017-financial-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3330670\" data-linked=\"Sequans -3.9% after revenues slip 19%\" data-tweet=\"$SQNS - Sequans -3.9% after revenues slip 19% https://seekingalpha.com/news/3330670-sequansminus-3_9-after-revenues-slip-19?source=tweet\" data-url=\"https://seekingalpha.com/news/3330670-sequansminus-3_9-after-revenues-slip-19\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330668\" data-ts=\"1518554091\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MCD\" target=\"_blank\">MCD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330668-mcdonalds-chicken-plan\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">McDonald&#39;s has a chicken plan</a></h4><ul> <li>McDonald's (<a href='https://seekingalpha.com/symbol/MCD' title='McDonald&#39;s Corporation'>MCD</a> <font color='red'>-0.6%</font>) wants to make chicken a top priority at the company, according to a leaked internal <a href=\"https://www.bloomberg.com/news/articles/2018-02-13/mcdonald-s-bets-that-better-chicken-can-keep-growth-run-going\" target=\"_blank\">memo</a>.</li> <li>The restaurant chain wants to highlight its products that consumers typically associate with Chick-fil-A, including Southern-style chicken sandwiches and tenders.</li> <li>The \"Better Chicken\" effort is also likely to de-emphasize the old McNuggets style to focus on chicken products with crispier coatings and juicier interiors.</li><li>The focus on chicken is seen as a strategic way for the company to stoke sales growth.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3330668\" data-linked=\"McDonald&#39;s has a chicken plan\" data-tweet=\"$MCD - McDonald&#39;s has a chicken plan https://seekingalpha.com/news/3330668-mcdonalds-chicken-plan?source=tweet\" data-url=\"https://seekingalpha.com/news/3330668-mcdonalds-chicken-plan\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>40&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330666\" data-ts=\"1518553756\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IBM\" target=\"_blank\">IBM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330666-ibm-sues-former-exec-moving-to-microsoft\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">IBM sues former exec moving to Microsoft</a></h4><ul><li>        IBM (NYSE:<a href='https://seekingalpha.com/symbol/IBM' title='International Business Machines Corporation'>IBM</a>) is <a href=\"https://www.reuters.com/article/us-ibm-microsoft-executives/ibm-sues-former-hr-boss-hired-by-microsoft-idUSKBN1FX0FW\" target=\"_blank\">suing</a> former human resources VP and Chief Diversity Officer Lindsay-Rae McIntyre alleging a violation of a one-year non-competitive agreement.</li><li>               Microsoft (NASDAQ:<a href='https://seekingalpha.com/symbol/MSFT' title='Microsoft Corporation'>MSFT</a>) named McIntyre as their new Chief Diversity Officer over the weekend. &nbsp;&nbsp;</li><li>               IBM&rsquo;s side: The company says McIntyre &ldquo;abruptly resigned to compete against IBM&rdquo; and possesses confidential and sensitive information about IBM&rsquo;s diversity and hiring strategies and tech and innovations.</li><li>               What IBM wants: IBM wants to enforce the non-competition agreement for the year and recover equity compensation forfeited by her alleged contractual violation.&nbsp;</li><li>               McIntyre&rsquo;s side: In a motion filed today, McIntyre says IBM has no evidence she has or will misappropriate any IBM information and that the company is covered by an ongoing NDA. She also says she informed IBM of the Microsoft job offer in January, which was when she was terminated.&nbsp;</li><li>               A judge has temporarily halted McIntyre&rsquo;s move to Microsoft until the mess is sorted out.&nbsp;</li><li>               Microsoft&rsquo;s side: &ldquo;We have no interest in any of IBM&rsquo;s confidential information.&rdquo; &nbsp;&nbsp;</li><li>IBM shares are&nbsp;<font color='red'>down 0.5%</font>.&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3330666\" data-linked=\"IBM sues former exec moving to Microsoft\" data-tweet=\"$IBM $IBM $MSFT - IBM sues former exec moving to Microsoft https://seekingalpha.com/news/3330666-ibm-sues-former-exec-moving-to-microsoft?source=tweet\" data-url=\"https://seekingalpha.com/news/3330666-ibm-sues-former-exec-moving-to-microsoft\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>68&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330665\" data-ts=\"1518553596\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FOSL\" target=\"_blank\">FOSL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330665-volatile-trading-on-fossil-ahead-of-earning\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Volatile trading on Fossil ahead of earning</a></h4><ul> <li>Fossil (NASDAQ:<a href='https://seekingalpha.com/symbol/FOSL' title='Fossil, Inc.'>FOSL</a>) is <font color='green'>up 7.62%</font> on a jolt of confidence from investors ahead of the company's earnings report due out after the market closes.</li> <li>Analysts expect the retailer to report revenue of $890M off a 6% decline in comparable sales and  EPS of $0.39.</li> <li>Bloomberg options data implies an up or down movement of 17%. Short interest stands at 46% of float.</li> <li>Fossil's full-year guidance on the wearables business could be crucial.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3330665\" data-linked=\"Volatile trading on Fossil ahead of earning\" data-tweet=\"$FOSL - Volatile trading on Fossil ahead of earning https://seekingalpha.com/news/3330665-volatile-trading-on-fossil-ahead-of-earning?source=tweet\" data-url=\"https://seekingalpha.com/news/3330665-volatile-trading-on-fossil-ahead-of-earning\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330659\" data-ts=\"1518551783\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OPNT\" target=\"_blank\">OPNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330659-technology-top-gainers-losers-of-2_55-pm-2-13-18\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2.55 pm (2/13/18)</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/OPNT' title='Opiant Pharmaceuticals, Inc.'>OPNT</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/VECO' title='Veeco Instruments Inc.'>VECO</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/EGAN' title='eGain Communications Corp.'>EGAN</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/INST' title='Instructure'>INST</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/AMBR' title='Amber Road, Inc.'>AMBR</a> <font color='green'>+12%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='red'>-31%</font>. <a href='https://seekingalpha.com/symbol/BBOX' title='Black Box Corporation'>BBOX</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/INPX' title='Inpixon'>INPX</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/QBAK' title='Qualstar Corporation'>QBAK</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/RVLT' title='Revolution Lighting Technologies, Inc.'>RVLT</a> <font color='red'>-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3330659\" data-linked=\"Technology - Top Gainers / Losers as of 2.55 pm (2/13/18)\" data-tweet=\"$OPNT $OPNT $VECO - Technology - Top Gainers / Losers as of 2.55 pm (2/13/18) https://seekingalpha.com/news/3330659-technology-top-gainers-losers-of-2_55-pm-2-13-18?source=tweet\" data-url=\"https://seekingalpha.com/news/3330659-technology-top-gainers-losers-of-2_55-pm-2-13-18\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:56 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330652\" data-ts=\"1518550337\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WFT\" target=\"_blank\">WFT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330652-weatherford-hits-52-week-low-barclays-downgrades\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Weatherford hits 52-week low as Barclays downgrades</a></h4><ul>     <li>Weatherford (<a href='https://seekingalpha.com/symbol/WFT' title='Weatherford International Ltd.'>WFT</a> <font color='red'>-6.5%</font>) sinks to a 52-week low after Barclays <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/18/02/11187450/barclays-slashes-weatherford-price-target-on-execution-\" target=\"_blank\">downgrades</a> shares to Equal Weight from Overweight with a $3.50 price target, slashed from $6, saying the company has been severely impaired after two decades of mismanagement, poor execution and a culture unaccustomed to accountability.</li>     <li>Barclays believes CEO&nbsp;Mark McCollum is the \"right man for the job\" but could be constrained by WFT's $7.1B in net debt and the low-hanging cost opportunities that already were picked up in the third year of a turnaround.</li>     <li>\"In light of the heightened execution risk and limited means to delever its balance sheet, shares of WFT should trade at a healthy discount to its larger peers, after which leaves little equity upside even after giving credit for planned asset sales and much of the targeted improvements, most of which will be implemented in 2019,\" the firm writes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3330652\" data-linked=\"Weatherford hits 52-week low as Barclays downgrades\" data-tweet=\"$WFT $WFTIQ - Weatherford hits 52-week low as Barclays downgrades https://seekingalpha.com/news/3330652-weatherford-hits-52-week-low-barclays-downgrades?source=tweet\" data-url=\"https://seekingalpha.com/news/3330652-weatherford-hits-52-week-low-barclays-downgrades\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330648\" data-ts=\"1518549149\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PAA\" target=\"_blank\">PAA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330648-plains-all-american-pipeline-upgraded-morgan-stanley-concerns-fade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Plains All American Pipeline upgraded at Morgan Stanley as concerns fade</a></h4><ul>     <li>Plains All American Pipeline (<a href='https://seekingalpha.com/symbol/PAA' title='Plains All American Pipeline, L.P.'>PAA</a> <font color='green'>+1.6%</font>) is higher after Morgan Stanley <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/18/02/11185328/as-plains-all-american-concerns-fade-morgan-stanley-see\" target=\"_blank\">upgrades</a> shares to Overweight from Equal Weight with a $26 price target, saying short-term concerns are fading with the focus shifting to debt paydown, rising producer volume and growth in 2018 and 2019.</li>     <li>Concerns about high S&amp;L expectations, 2018 guidance decreases, volume degradation arising from competitive pressure and funding availability all have faded, Stanley says.</li>     <li>After lowering its distribution twice, PAA is now in a strong position to fulfill its plan to reduce debt by $1.4B over the next five quarters, the firm says.</li>     <li>Stanley also upgrades Plains GP (<a href='https://seekingalpha.com/symbol/PAGP' title='Plains GP Holdings, LP'>PAGP</a> <font color='green'>+2.4%</font>) to Overweight from Equal Weight.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3330648\" data-linked=\"Plains All American Pipeline upgraded at Morgan Stanley as concerns fade\" data-tweet=\"$PAA $PAA $PAGP - Plains All American Pipeline upgraded at Morgan Stanley as concerns fade https://seekingalpha.com/news/3330648-plains-all-american-pipeline-upgraded-morgan-stanley-concerns-fade?source=tweet\" data-url=\"https://seekingalpha.com/news/3330648-plains-all-american-pipeline-upgraded-morgan-stanley-concerns-fade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330645\" data-ts=\"1518548647\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZN\" target=\"_blank\">ZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330645-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ZN' title='Zion Oil & Gas Inc'>ZN</a> <font color='green'>+28%</font>. <a href='https://seekingalpha.com/symbol/OSN' title='Ossen Innovation Co., Ltd.'>OSN</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/BXE' title='Bellatrix Exploration Ltd'>BXE</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/CDXC' title='ChromaDex Inc.'>CDXC</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/UEC' title='Uranium Energy Corp'>UEC</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CGG-OLD' title='CGG'>CGG-OLD</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/USAU' title='U.S. Gold Corp.'>USAU</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/ACET' title='Aceto Corporation'>ACET</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/WFT' title='Weatherford International Ltd.'>WFT</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/MCF' title='Contango Oil & Gas Company'>MCF</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3330645\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$ZN $ZN $OSN - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3330645-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3330645-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330639\" data-ts=\"1518547211\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KDMN\" target=\"_blank\">KDMN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330639-investors-underwhelmed-mid-stage-data-on-kadmons-kd025-in-ipf-shares-down-13\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Investors underwhelmed with mid-stage data on Kadmon&#39;s KD025 in IPF; shares down 13%</a></h4><ul><li>Kadmon Holdings (<a href='https://seekingalpha.com/symbol/KDMN' title='Kadmon Holdings'>KDMN</a> <font color='red'>-12.6%</font>) slumps on more than a 5x surge in volume after it reported <a href=\"https://www.sec.gov/Archives/edgar/data/1557142/000155714218000011/kdmn-20180212xex99_1.htm\" target=\"_blank\">top-line data</a> from an ongoing Phase 2 clinical trial assessing KD025 in patients with idiopathic pulmonary fibrosis &#40;IPF&#41; who were previously treated with (or offered) pirfenidone (Roche's <a href=\"https://www.esbriet.com/\" target=\"_blank\">Esbriet</a>)&nbsp;and/or nintedanib (Boehringer Ingelheim's <a href=\"https://www.ofev.com/\" target=\"_blank\">OFEV</a>).</li><li>20 evaluable patients receiving KD025 experienced a median decline in forced vital capacity &#40;FVC&#41;, a measure of lung function, of 48 mL at week 24 compared to a median decline of 175 mL in patients receiving best supportive care &#40;BSC&#41;.</li><li>At week 24, 20% of KD025-treated patients progressed, as determined by at least a 5% decline in FVC%, compared to 44% for BSC.</li><li>On the safety front, KD025 was well-tolerated with no drug-related serious adverse events observed.</li><li>The results will be submitted for presentation at the American Thoracic Society International Conference in May.</li><li>Small molecule&nbsp;<a href=\"http://kadmon.com/research-development/pipeline/\" target=\"_blank\">KD025</a>&nbsp;inhibits an pro-inflammatory enzyme called rho-associated coiled-coil kinase 2 (ROCK2). Inhibiting the enzyme&nbsp;<a href=\"http://www.ncbi.nlm.nih.gov/pubmed/25385601\" target=\"_blank\">down-regulates</a>&nbsp;the ability of the immune system's T cells to secrete IL-21 and IL-17, thereby dampening the immune response.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3210245-kadmon-launches-mid-stage-study-kd025-psoriasis\" target=\"_blank\">Kadmon launches mid-stage study of KD025 in psoriasis</a> (Sept. 21, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3330639\" data-linked=\"Investors underwhelmed with mid-stage data on Kadmon&#39;s KD025 in IPF; shares down 13%\" data-tweet=\"$KDMN - Investors underwhelmed with mid-stage data on Kadmon&#39;s KD025 in IPF; shares down 13% https://seekingalpha.com/news/3330639-investors-underwhelmed-mid-stage-data-on-kadmons-kd025-in-ipf-shares-down-13?source=tweet\" data-url=\"https://seekingalpha.com/news/3330639-investors-underwhelmed-mid-stage-data-on-kadmons-kd025-in-ipf-shares-down-13\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330634\" data-ts=\"1518545416\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/M\" target=\"_blank\">M</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330634-trading-action-on-macys-picks-up\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trading action on Macy&#39;s picks up</a></h4><ul> <li>Macy's (NYSE:<a href='https://seekingalpha.com/symbol/M' title='Macy&#39;s Inc.'>M</a>) is <font color='green'>up 2.60%</font> on above-average volume.</li> <li>Bloomberg reports that options volume on Macy's is almost double normal activity after a large March contract trade.</li> <li>Macy's is due to report Q4 earnings on February 27.</li><li>Shares of Macy's are down 1.59% YTD.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3330634\" data-linked=\"Trading action on Macy&#39;s picks up\" data-tweet=\"$M - Trading action on Macy&#39;s picks up https://seekingalpha.com/news/3330634-trading-action-on-macys-picks-up?source=tweet\" data-url=\"https://seekingalpha.com/news/3330634-trading-action-on-macys-picks-up\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330629\" data-ts=\"1518544825\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GHL\" target=\"_blank\">GHL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330629-financials-top-5-gainers-losers-of-1-00-pm-02-13-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM (02/13/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CH' title='Aberdeen Chile Fund'>CH</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/GHL' title='Greenhill & Co., Inc.'>GHL</a> <font color='green'>+7%</font>.<a href='https://seekingalpha.com/symbol/GDOT' title='Green Dot Corporation'>GDOT</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/VBFC' title='Village Bank and Trust Financial Corp.'>VBFC</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/ONDK' title='OnDeck Capital'>ONDK</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ARCT' title='Arcturus Therapeutics Ltd.'>ARCT</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/BHF' title='Brighthouse Financial, Inc.'>BHF</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/APAM' title='Artisan Partners Asset Management'>APAM</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3330629\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM (02/13/2018)\" data-tweet=\"$GHL $CH $GHL - Financials - Top 5 Gainers / Losers as of 1:00 PM (02/13/2018) https://seekingalpha.com/news/3330629-financials-top-5-gainers-losers-of-1-00-pm-02-13-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3330629-financials-top-5-gainers-losers-of-1-00-pm-02-13-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330626\" data-ts=\"1518544248\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CATB\" target=\"_blank\">CATB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330626-midday-gainers-losers-2-13-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers (2/13/2018)</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CATB' title='Catabasis Pharmaceuticals'>CATB</a> <font color='green'>+56%</font>. <a href='https://seekingalpha.com/symbol/AQMS' title='Aqua Metals'>AQMS</a> <font color='green'>+30%</font>. <a href='https://seekingalpha.com/symbol/GNC' title='GNC Holdings, Inc.'>GNC</a> <font color='green'>+30%</font>. <a href='https://seekingalpha.com/symbol/TYHT' title='Shineco, Inc.'>TYHT</a> <font color='green'>+26%</font>. <a href='https://seekingalpha.com/symbol/OPNT' title='Opiant Pharmaceuticals, Inc.'>OPNT</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/OSN' title='Ossen Innovation Co., Ltd.'>OSN</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/CHGG' title='Chegg, Inc.'>CHGG</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/AXON' title='Axovant Sciences'>AXON</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/VECO' title='Veeco Instruments Inc.'>VECO</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/UAA' title='Under Armour, Inc.'>UAA</a> <font color='green'>+15%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/DARE' title='Dare Bioscience, Inc.'>DARE</a> <font color='red'>-41%</font>. <a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='red'>-31%</font>. <a href='https://seekingalpha.com/symbol/BASI' title='Bioanalytical Systems, Inc.'>BASI</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/AFMD' title='Affimed Therapeutics'>AFMD</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/ZSAN' title='Zosano Pharma'>ZSAN</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/INPX' title='Inpixon'>INPX</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/KDMN' title='Kadmon Holdings'>KDMN</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/USAU' title='U.S. Gold Corp.'>USAU</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/EMAN' title='eMagin Corporation'>EMAN</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a> <font color='red'>-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3330626\" data-linked=\"Midday Gainers / Losers (2/13/2018)\" data-tweet=\"$CATB $CATB $AQMS - Midday Gainers / Losers (2/13/2018) https://seekingalpha.com/news/3330626-midday-gainers-losers-2-13-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3330626-midday-gainers-losers-2-13-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330622\" data-ts=\"1518543512\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VIRT\" target=\"_blank\">VIRT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330622-virtu-financial-gets-bump-from-mark-cuban\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Virtu Financial gets bump from Mark Cuban</a></h4><ul><li>Speaking on CNBC, Mark Cuban says he's picked up shares of Virtu Financial (<a href='https://seekingalpha.com/symbol/VIRT' title='Virtu Financial, Inc.'>VIRT</a> <font color='green'>+1.5%</font>).</li><li>While most of the stock world zigged lower last week, shares of Virtu zagged sharply higher amid blowout Q4 earnings and the idea that February's big jump in volatility will boost business.</li><li>VIRT now&nbsp;<font color='green'>up 52%</font>&nbsp;in 2018.</li></ul><div class=\"tiny-share-widget\" data-id=\"3330622\" data-linked=\"Virtu Financial gets bump from Mark Cuban\" data-tweet=\"$VIRT - Virtu Financial gets bump from Mark Cuban https://seekingalpha.com/news/3330622-virtu-financial-gets-bump-from-mark-cuban?source=tweet\" data-url=\"https://seekingalpha.com/news/3330622-virtu-financial-gets-bump-from-mark-cuban\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330621\" data-ts=\"1518543109\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PUBGY\" target=\"_blank\">PUBGY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330621-publicisplus-3_9-after-sealing-global-deal-to-rep-mercedes-benz\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Publicis +3.9% after sealing global deal to rep Mercedes-Benz</a></h4><ul>     <li>Publicis Groupe (<a href='https://seekingalpha.com/symbol/PUBGY' title='Publicis Groupe S.A. ADR'>OTCQX:PUBGY</a>) is <font color='green'>up 3.9%</font> after it sealed what it calls one of its most important wins in years -- a multi-year contract to become <a href=\"https://www.reuters.com/article/us-publicis-daimler-advertising/publicis-shares-jump-after-mercedes-benz-global-digital-agency-win-idUSKCN1FX2DR\" target=\"_blank\">global digital agency for Mercedes-Benz</a>.</li>     <li>Terms were undisclosed, but Mereces-Benz parent Daimler is one of the world's top 10 advertisers and spent more than $5B in 2016, AdAge says.</li>     <li>The win comes at the expense of bigger rivals WPP (NYSE:<a href='https://seekingalpha.com/symbol/WPP' title='WPP Plc'>WPP</a>) and Omnicom (NYSE:<a href='https://seekingalpha.com/symbol/OMC' title='Omnicom Group Inc.'>OMC</a>). Publicis spent about six months negotiating at the holding company level, it said in an internal memo.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3330621\" data-linked=\"Publicis +3.9% after sealing global deal to rep Mercedes-Benz\" data-tweet=\"$PUBGY $PUBGY $WPP - Publicis +3.9% after sealing global deal to rep Mercedes-Benz https://seekingalpha.com/news/3330621-publicisplus-3_9-after-sealing-global-deal-to-rep-mercedes-benz?source=tweet\" data-url=\"https://seekingalpha.com/news/3330621-publicisplus-3_9-after-sealing-global-deal-to-rep-mercedes-benz\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330618\" data-ts=\"1518542365\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MLM\" target=\"_blank\">MLM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330618-martin-marietta-moves-up-after-strong-q4-earnings-beat-upside-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Martin Marietta moves up after strong Q4 earnings beat, upside guidance</a></h4><ul>     <li>Martin Marietta Materials (<a href='https://seekingalpha.com/symbol/MLM' title='Martin Marietta Materials Inc.'>MLM</a> <font color='green'>+3.7%</font>) shoots higher after posting much better than expected <a href=\"https://seekingalpha.com/news/3330427-martin-marietta-materials-beats-0_41-misses-revenue\" target=\"_blank\">Q4 earnings</a> with revenues rising 2.5% Y/Y to $911M, including solid pricing growth across all product lines and segments.</li>     <li>MLM says it delivered record revenues, profitability and EPS for both Q4 and FY 2017, and says the ongoing pricing improvements helped spark a 290-bp expansion in Q4 consolidated gross margin to 26.8% vs. the prior-year quarter.</li>     <li>Following strong Q4 results, MLM issues upside guidance for FY 2018, seeing revenues of $4.16B-$4.36B vs. $4.07B analyst consensus estimate.</li>     <li>MLM says it remains confident the U.S. is \"in the midst of a steady multi-year construction recovery.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3330618\" data-linked=\"Martin Marietta moves up after strong Q4 earnings beat, upside guidance\" data-tweet=\"$MLM - Martin Marietta moves up after strong Q4 earnings beat, upside guidance https://seekingalpha.com/news/3330618-martin-marietta-moves-up-after-strong-q4-earnings-beat-upside-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3330618-martin-marietta-moves-up-after-strong-q4-earnings-beat-upside-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330617\" data-ts=\"1518542333\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NSM\" target=\"_blank\">NSM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330617-investors-sour-on-nationstar-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Investors sour on Nationstar deal</a></h4><ul><li>Nationstar Mortgage (NYSE:<a href='https://seekingalpha.com/symbol/NSM' title='Nationstar Mortgage Holdings'>NSM</a>) is<font color='red'> lower by 2.05%&nbsp;</font>to $16.75 after announcing a merger with WMIH Corp. (WMIH) for either $18 per share in cash, or shares of WMIH.</li><li>The deal is dilutive, says Piper's Kevin Barker, downgrading NSM to Underweight and cutting the price target to $13.50 from $18. He figures it will reduce book value per share to $13.09 to $16.22.</li><li>There's also the addition of $826M in debt to the balance sheet, and questions over whether the DTA can be utilized quickly.</li><li>Source: Bloomberg</li><li>WMIH, by the way, is&nbsp;<font color='green'>up 56.4%</font>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3330439-wmih-corp-finds-target-nationstar-mortgage\" target=\"_blank\">WMIH Corp. finds its target in Nationstar Mortgage</a> (Feb. 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3330617\" data-linked=\"Investors sour on Nationstar deal\" data-tweet=\"$NSM $NSM $COOP - Investors sour on Nationstar deal https://seekingalpha.com/news/3330617-investors-sour-on-nationstar-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3330617-investors-sour-on-nationstar-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330614\" data-ts=\"1518541954\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MBRX\" target=\"_blank\">MBRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330614-moleculin-teams-up-emory-u-to-develop-wp1066-for-pediatric-brain-cancer-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Moleculin teams up with Emory U. to develop WP1066 for pediatric brain cancer; shares up 2%</a></h4><ul><li>Moleculin Biotech (<a href='https://seekingalpha.com/symbol/MBRX' title='Moleculin Biotech, Inc.'>MBRX</a> <font color='green'>+2.2%</font>) inks a research <a href=\"https://seekingalpha.com/pr/17073086-moleculin-announces-collaboration-emory-university-develop-novel-treatment-pediatric-brain\" target=\"_blank\">agreement</a> with Emory University aimed at developing candidate WP1066 for the potential treatment of a pediatric malignant primary brain tumor called medulloblastoma. Financial terms are not disclosed.</li><li><a href=\"http://www.moleculin.com/technology/wp1066-2/\" target=\"_blank\">WP1066</a> inhibits a dual protein called pSTAT3 which plays a key role in gene transcription. Inhibiting the formation of pSTAT3 prevents the start of unwanted gene transcription in cancer cells which controls the cancer.</li></ul><div class=\"tiny-share-widget\" data-id=\"3330614\" data-linked=\"Moleculin teams up with Emory U. to develop WP1066 for pediatric brain cancer; shares up 2%\" data-tweet=\"$MBRX - Moleculin teams up with Emory U. to develop WP1066 for pediatric brain cancer; shares up 2% https://seekingalpha.com/news/3330614-moleculin-teams-up-emory-u-to-develop-wp1066-for-pediatric-brain-cancer-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3330614-moleculin-teams-up-emory-u-to-develop-wp1066-for-pediatric-brain-cancer-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:12 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330611\" data-ts=\"1518541262\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KBSF\" target=\"_blank\">KBSF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330611-consumer-top-gainers-losers-of-12-00-pm-2-13-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm (2/13/2018)</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/KBSF' title='KBS Fashion Group Limited'>KBSF</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/UAA' title='Under Armour, Inc.'>UAA</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/UA' title='Under Armour, Inc. Class C'>UA</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/ATR' title='AptarGroup Inc.'>ATR</a> <font color='green'>+11%</font>. AOI <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ICON' title='Iconix Brand Group, Inc.'>ICON</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/ABAC-OLD' title='Renmin Tianli Group'>ABAC-OLD</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/DAN' title='Dana, Inc.'>DAN</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3330611\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm (2/13/2018)\" data-tweet=\"$KBSF $KBSF $UAA - Consumer - Top Gainers / Losers as of 12:00 pm (2/13/2018) https://seekingalpha.com/news/3330611-consumer-top-gainers-losers-of-12-00-pm-2-13-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3330611-consumer-top-gainers-losers-of-12-00-pm-2-13-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330612\" data-ts=\"1518541197\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/X\" target=\"_blank\">X</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330612-steel-sector-moving-trump-calls-for-tariffs-to-fix-decimated-industry\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Steel sector moving as Trump calls for tariffs to fix &#39;decimated&#39; industry</a></h4><ul><li>Steel stocks (<a href='https://seekingalpha.com/symbol/SLX' title='VanEck Vectors Steel ETF'>SLX</a> <font color='green'>+0.9%</font>) are higher as Pres. Trump talks up the industry, saying the U.S. is being \"decimated\" by countries dumping their steel products and calling for tariffs as an option to counter the problem.</li><li>Trump says U.S. steel companies are \"hanging on for their lives,\" and he wants to make sure that \"we still have a steel industry.\"</li><li><a href='https://seekingalpha.com/symbol/X' title='United States Steel Corporation'>X</a> <font color='green'>+2.4%</font>, <a href='https://seekingalpha.com/symbol/MT' title='ArcelorMittal'>MT</a> <font color='green'>+2.2%</font>, <a href='https://seekingalpha.com/symbol/CLF' title='Cleveland-Cliffs, Inc.'>CLF</a> <font color='green'>+3.1%</font>, <a href='https://seekingalpha.com/symbol/AKS' title='AK Steel Holding Corp'>AKS</a> <font color='green'>+1.6%</font>, <a href='https://seekingalpha.com/symbol/NUE' title='Nucor Corporation'>NUE</a> <font color='green'>+1.5%</font>, <a href='https://seekingalpha.com/symbol/STLD' title='Steel Dynamics, Inc.'>STLD</a> <font color='green'>+1.4%</font>, <a href='https://seekingalpha.com/symbol/SCHN' title='Schnitzer Steel Industries, Inc.'>SCHN</a> <font color='green'>+1.6%</font>, <a href='https://seekingalpha.com/symbol/RS' title='Reliance Steel & Aluminum Co.'>RS</a> <font color='green'>+1.1%</font>, <a href='https://seekingalpha.com/symbol/WOR' title='Worthington Industries, Inc.'>WOR</a> <font color='green'>+1.3%</font>.</li><li>Source:&nbsp;Bloomberg First Word</li></ul><div class=\"tiny-share-widget\" data-id=\"3330612\" data-linked=\"Steel sector moving as Trump calls for tariffs to fix &#39;decimated&#39; industry\" data-tweet=\"$X $SLX $X - Steel sector moving as Trump calls for tariffs to fix &#39;decimated&#39; industry https://seekingalpha.com/news/3330612-steel-sector-moving-trump-calls-for-tariffs-to-fix-decimated-industry?source=tweet\" data-url=\"https://seekingalpha.com/news/3330612-steel-sector-moving-trump-calls-for-tariffs-to-fix-decimated-industry\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>85&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330613\" data-ts=\"1518541068\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PARF\" target=\"_blank\">PARF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330613-paradise-explores-strategic-alternatives\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Paradise explores strategic alternatives</a></h4><ul>     <li>Paradise (<a href='https://seekingalpha.com/symbol/PARF' title='Paradise, Inc.'>OTCPK:PARF</a> <font color='green'>+3.5%</font>) Board is exploring and evaluating strategic alternatives for the Company, including a possible merger or sale of, or acquisition or other strategic investment by, the Company.</li>     <li>The Board of Paradise has retained Hyde Park Capital as financial advisor to assist in this process.</li>     <li>The Company has not set a timetable for completion of the evaluation process or made a decision to pursue any particular strategic alternative.</li><li><a href=\"https://seekingalpha.com/pr/17073430-paradise-inc-explores-strategic-alternatives\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3330613\" data-linked=\"Paradise explores strategic alternatives\" data-tweet=\"$PARF - Paradise explores strategic alternatives https://seekingalpha.com/news/3330613-paradise-explores-strategic-alternatives?source=tweet\" data-url=\"https://seekingalpha.com/news/3330613-paradise-explores-strategic-alternatives\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:57 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330608\" data-ts=\"1518540570\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MEIP\" target=\"_blank\">MEIP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330608-mei-pharmas-early-stage-study-of-meminus-344-in-her2-negative-breast-cancer-to-continue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MEI Pharma&#39;s early-stage study of ME-344 in HER2-negative breast cancer to continue as planned; shares up 1%</a></h4><ul><li>Based on an interim data review, a <a href=\"https://clinicaltrials.gov/ct2/show/NCT02806817?term=me-344&amp;rank=3\" target=\"_blank\">Phase 1 clinical trial</a> assessing MEI Pharma's (<a href='https://seekingalpha.com/symbol/MEIP' title='MEI Pharma, Inc.'>MEIP</a> <font color='green'>+1.4%</font>)&nbsp;ME-344 in patients with HER2-negative breast cancer will continue as planned. According to ClinicalTrials.gov, the estimated primary completion date is August.</li><li>The open-label study is evaluating the combination of ME-344 and Roche's Avastin (bevacizumab) compared to Avastin + saline in 40 patients.</li><li><a href=\"http://www.meipharma.com/our-programs/me-344\" target=\"_blank\">ME-344</a>, a mitochondrial inhibitor, is based on a class of plant molecules called <a href=\"https://en.wikipedia.org/wiki/Isoflavones\" target=\"_blank\">isoflavones</a>. It targets ATP production (energy source for cells) in mitochondria in cancer cells with leads to cell death via a process called destructive autophagy (the cell consumes itself).</li></ul><div class=\"tiny-share-widget\" data-id=\"3330608\" data-linked=\"MEI Pharma&#39;s early-stage study of ME-344 in HER2-negative breast cancer to continue as planned; shares up 1%\" data-tweet=\"$MEIP - MEI Pharma&#39;s early-stage study of ME-344 in HER2-negative breast cancer to continue as planned; shares up 1% https://seekingalpha.com/news/3330608-mei-pharmas-early-stage-study-of-meminus-344-in-her2-negative-breast-cancer-to-continue?source=tweet\" data-url=\"https://seekingalpha.com/news/3330608-mei-pharmas-early-stage-study-of-meminus-344-in-her2-negative-breast-cancer-to-continue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330604\" data-ts=\"1518540048\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARCH\" target=\"_blank\">ARCH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330604-arch-coalminus-2-after-beating-on-earnings-missing-on-revenues\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arch Coal -2% after beating on earnings, missing on revenues</a></h4><ul>     <li>Arch Coal (<a href='https://seekingalpha.com/symbol/ARCH' title='Arch Coal Inc'>ARCH</a> <font color='red'>-2.4%</font>) is lower after reporting mixed <a href=\"https://seekingalpha.com/news/3330415-arch-coal-beats-1_79-misses-revenue\" target=\"_blank\">Q4 results</a>, including better than expected earnings but a decline in revenues.</li>     <li>Arch's $81.3M Q4 profit was higher than the $33.4M profit from the prior-year quarter but much of the improvement was due to a $34.8M net tax benefit associated with alternative minimum tax credits that became refundable under the recent tax law changes.</li>     <li>Arch initiates FY 2018 sales volume guidance of 92M-99M tons, in-line with 2017 sales volumes; it expects to sell 86M-92M tons of thermal coal this year, with thermal sales ~82% committed for FY 2018, and forecasts sales of 6.4M-7M tons of metallurgical coal.</li>     <li>Cash cost per ton sold in Arch's Metallurgical and Powder River Basin segments are expected to be similar to 2017 levels.</li>     <li>The company also raises its quarterly dividend to $0.40/share from $0.35.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3330604\" data-linked=\"Arch Coal -2% after beating on earnings, missing on revenues\" data-tweet=\"$ARCH - Arch Coal -2% after beating on earnings, missing on revenues https://seekingalpha.com/news/3330604-arch-coalminus-2-after-beating-on-earnings-missing-on-revenues?source=tweet\" data-url=\"https://seekingalpha.com/news/3330604-arch-coalminus-2-after-beating-on-earnings-missing-on-revenues\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:40 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330602\" data-ts=\"1518539508\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NK\" target=\"_blank\">NK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330602-early-stage-study-underway-assessing-nantkwests-her2-tank-in-brain-cancer-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Early-stage study underway assessing Nantkwest&#39;s HER2.taNK in brain cancer; shares up 2%</a></h4><ul><li>The <a href=\"https://seekingalpha.com/pr/17072939-nantkwest-frankfurt-university-hospital-announce-first-human-dosing-shelf-her2-tank-car\" target=\"_blank\">first patient</a> has been dosed in a <a href=\"https://clinicaltrials.gov/ct2/show/NCT03383978?term=NCT03383978&amp;rank=1\" target=\"_blank\">Phase 1 clinical trial</a> evaluating NantKwest's (<a href='https://seekingalpha.com/symbol/NK' title='NantKwest'>NK</a> <font color='green'>+1.5%</font>) natural killer cell-based immuno-oncology therapy HER2.taNK in glioblastoma patients.</li><li>The open-label 30-subject study will assess the safety, tolerability and efficacy of intracranial injection of HER2.taNK as monotherapy in patients with recurrent HER2+ glioblastoma at a single site in Germany. According to ClinicalTrials.gov, the estimated primary completion date is December 2019.</li><li>HER2.taNK is designed to deliver precise tumor-cell specificity via the use of a CAR (chimeric antigen receptor) construct employing a HER2-specific antibody fragment.</li></ul><div class=\"tiny-share-widget\" data-id=\"3330602\" data-linked=\"Early-stage study underway assessing Nantkwest&#39;s HER2.taNK in brain cancer; shares up 2%\" data-tweet=\"$NK - Early-stage study underway assessing Nantkwest&#39;s HER2.taNK in brain cancer; shares up 2% https://seekingalpha.com/news/3330602-early-stage-study-underway-assessing-nantkwests-her2-tank-in-brain-cancer-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3330602-early-stage-study-underway-assessing-nantkwests-her2-tank-in-brain-cancer-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330591\" data-ts=\"1518538117\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GRUB\" target=\"_blank\">GRUB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330591-grubhub-expands-presence-in-foursquare-app-bigger-partnership\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GrubHub expands presence in Foursquare app with bigger partnership</a></h4><ul>   <li>GrubHub (<a href=\"http://seekingalpha.com/symbol/GRUB\" target=\"_blank\">GRUB</a> <font color='green'>+2%</font>) has an <a href=\"https://seekingalpha.com/pr/17073424-grubhub-expands-partnership-foursquare-bring-restaurant-delivery-users-nationwide\" target=\"_blank\">expanded deal with Foursquare</a> that brings food ordering into listing on Foursquare's City Guide.</li>    <li>Users browsing restaurants on Foursquare can click an \"order now\" button to quickly get a food order from their location of choice.</li>    <li>Meanwhile, shared data will help both companies track trending foods and restaurants and help both companies improve discovery for users.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3330591\" data-linked=\"GrubHub expands presence in Foursquare app with bigger partnership\" data-tweet=\"$GRUB - GrubHub expands presence in Foursquare app with bigger partnership https://seekingalpha.com/news/3330591-grubhub-expands-presence-in-foursquare-app-bigger-partnership?source=tweet\" data-url=\"https://seekingalpha.com/news/3330591-grubhub-expands-presence-in-foursquare-app-bigger-partnership\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330559\" data-ts=\"1518537655\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CATB\" target=\"_blank\">CATB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330559-healthcare-top-5-gainers-losers-of-11-00-2-13-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am (2/13/2018)</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CATB' title='Catabasis Pharmaceuticals'>CATB</a> <font color='green'>+70%</font>. <a href='https://seekingalpha.com/symbol/TYHT' title='Shineco, Inc.'>TYHT</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/TTNP' title='Titan Pharmaceuticals, Inc.'>TTNP</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/AMPE' title='Ampio Pharmaceuticals, Inc.'>AMPE</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/CBAY' title='CymaBay Therapeutics'>CBAY</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/DARE' title='Dare Bioscience, Inc.'>DARE</a> <font color='red'>-40%</font>. <a href='https://seekingalpha.com/symbol/AFMD' title='Affimed Therapeutics'>AFMD</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/ZSAN' title='Zosano Pharma'>ZSAN</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/NVTA' title='Invitae'>NVTA</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a> <font color='red'>-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3330559\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am (2/13/2018)\" data-tweet=\"$CATB $CATB $TYHT - Healthcare - Top 5 Gainers / Losers as of 11:00 am (2/13/2018) https://seekingalpha.com/news/3330559-healthcare-top-5-gainers-losers-of-11-00-2-13-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3330559-healthcare-top-5-gainers-losers-of-11-00-2-13-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330585\" data-ts=\"1518537464\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZSAN\" target=\"_blank\">ZSAN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330585-zosano-pharma-readies-stock-offering-shares-down-14\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zosano Pharma readies stock offering; shares down 14%</a></h4><ul><li>Thinly traded nano cap Zosano Pharma (<a href='https://seekingalpha.com/symbol/ZSAN' title='Zosano Pharma'>ZSAN</a> <font color='red'>-13.5%</font>) slumps on 60% higher volume, albeit on turnover of only ~83K shares, in reaction to its planned 12.5M-share <a href=\"https://www.sec.gov/Archives/edgar/data/1587221/000119312518040699/d479354ds1a.htm\" target=\"_blank\">stock offering</a>. Price and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3330585\" data-linked=\"Zosano Pharma readies stock offering; shares down 14%\" data-tweet=\"$ZSAN - Zosano Pharma readies stock offering; shares down 14% https://seekingalpha.com/news/3330585-zosano-pharma-readies-stock-offering-shares-down-14?source=tweet\" data-url=\"https://seekingalpha.com/news/3330585-zosano-pharma-readies-stock-offering-shares-down-14\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:57 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330584\" data-ts=\"1518537208\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BLFS\" target=\"_blank\">BLFS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330584-biolife-inks-supply-agreement-milliporesigma-shares-up-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioLife inks supply agreement with MilliporeSigma; shares up 4%</a></h4><ul><li>BioLife Solutions (<a href='https://seekingalpha.com/symbol/BLFS' title='BioLife Solutions, Inc.'>BLFS</a> <font color='green'>+4%</font>) inks an <a href=\"https://seekingalpha.com/pr/17072894-biolife-solutions-executes-oem-agreement-milliporesigma\" target=\"_blank\">OEM agreement</a> with Merck KGaA's (<a href='https://seekingalpha.com/symbol/MKGAF' title='Merck KGaA'>OTCPK:MKGAF</a>) MilliporeSigma unit to supply its CryoStor cell freeze media and HypoThermosol cell storage and shipping media under the MilliporeSigma label. Financial terms are not disclosed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3330584\" data-linked=\"BioLife inks supply agreement with MilliporeSigma; shares up 4%\" data-tweet=\"$BLFS $BLFS $MKGAF - BioLife inks supply agreement with MilliporeSigma; shares up 4% https://seekingalpha.com/news/3330584-biolife-inks-supply-agreement-milliporesigma-shares-up-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3330584-biolife-inks-supply-agreement-milliporesigma-shares-up-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330583\" data-ts=\"1518536996\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TWTR\" target=\"_blank\">TWTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330583-twitterplus-7_3-and-retesting-highs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Twitter +7.3% and retesting highs</a></h4><ul>   <li>Twitter (NYSE:<a href='https://seekingalpha.com/symbol/TWTR' title='Twitter, Inc.'>TWTR</a>) shares are up sharply and still moving, <font color='green'>+7.3%</font>, charging toward their 52-week high.</li>    <li>There's no particular catalyst, though call options are active.</li>    <li>Shares hit a 52-week high of $35 just last Thursday; they're <font color='green'>up 108%</font> over the past 12 months.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3330583\" data-linked=\"Twitter +7.3% and retesting highs\" data-tweet=\"$TWTR - Twitter +7.3% and retesting highs https://seekingalpha.com/news/3330583-twitterplus-7_3-and-retesting-highs?source=tweet\" data-url=\"https://seekingalpha.com/news/3330583-twitterplus-7_3-and-retesting-highs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>31&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330574\" data-ts=\"1518535064\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LGIH\" target=\"_blank\">LGIH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330574-wedbush-buys-dip-in-housing\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wedbush buys the dip in housing</a></h4><ul><li>Homebuilders and their suppliers had a big 2017, but have gotten off to a bad start this year, with concern about higher interest rates making for a good excuse to sell.</li><li>Wedbush's Jay McCanless upgrades LGI Homes (<a href='https://seekingalpha.com/symbol/LGIH' title='LGI Homes, Inc.'>LGIH</a> <font color='green'>+0.8%</font>) and Beazer Homes (<a href='https://seekingalpha.com/symbol/BZH' title='Beazer Homes USA, Inc.'>BZH</a> <font color='green'>+2%</font>) to Outperform, noting the focus of both on entry-level homebuyers.</li><li>He also boosts Beacon Roofing Supply (<a href='https://seekingalpha.com/symbol/BECN' title='Beacon Roofing Supply, Inc.'>BECN</a> <font color='green'>+1.2%</font>), saying pricing power looks to be improving this year.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3330574\" data-linked=\"Wedbush buys the dip in housing\" data-tweet=\"$LGIH $LGIH $BZH - Wedbush buys the dip in housing https://seekingalpha.com/news/3330574-wedbush-buys-dip-in-housing?source=tweet\" data-url=\"https://seekingalpha.com/news/3330574-wedbush-buys-dip-in-housing\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:17 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330571\" data-ts=\"1518534655\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RAD\" target=\"_blank\">RAD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330571-rite-aid-and-freds-perky-after-walgreens-abc-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rite Aid and Fred&#39;s perky after Walgreens-ABC report</a></h4><ul> <li>Drugstore stocks Rite Aid (NYSE:<a href='https://seekingalpha.com/symbol/RAD' title='Rite Aid Corporation'>RAD</a>) and Fred's (NASDAQ:<a href='https://seekingalpha.com/symbol/FRED' title='Fred&#39;s, Inc.'>FRED</a>) are both a little perky after <a href=\"https://seekingalpha.com/news/3330373-amerisourcebergen-plus-22-percent-report-walgreens-buyout-talk\" target=\"_blank\">reports</a> on Walgreens' interest in AmerisourceBergen</li> <li>Rite Aid (<a href='https://seekingalpha.com/symbol/RAD' title='Rite Aid Corporation'>RAD</a>) is <font color='green'>up 1.8%</font> in a down market overall and Fred's is <font color='green'>1.1% higher</font>.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3330475-amerisourcebergens-gain-mckesson-cardinals-pain-red-potential-interest-abc-walgreens\" target=\"_blank\">AmerisourceBergen's gain is McKesson and Cardinal's pain, both in the red on potential interest in ABC by Walgreens</a> (Feb. 13)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3330534-wba-takeout-amerisourcebergen-boost-non-gaap-eps-10-percent-mizuho\" target=\"_blank\">WBA takeout of AmerisourceBergen could boost non-GAAP EPS 10% - Mizuho</a> (Feb. 13)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3330571\" data-linked=\"Rite Aid and Fred&#39;s perky after Walgreens-ABC report\" data-tweet=\"$RAD $RAD $FRED - Rite Aid and Fred&#39;s perky after Walgreens-ABC report https://seekingalpha.com/news/3330571-rite-aid-and-freds-perky-after-walgreens-abc-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3330571-rite-aid-and-freds-perky-after-walgreens-abc-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>31&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330564\" data-ts=\"1518534164\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CATB\" target=\"_blank\">CATB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330564-catabasis-pharmas-edasalonexent-shows-positive-effect-in-mid-stage-dmd-study-shares-up-62\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Catabasis Pharma&#39;s edasalonexent shows positive effect in mid-stage DMD study; shares up 62%</a></h4><ul><li>Thinly traded nano cap Catabasis Pharmaceuticals (<a href='https://seekingalpha.com/symbol/CATB' title='Catabasis Pharmaceuticals'>CATB</a> <font color='green'>+61.6%</font>) is up on a whopping 34x surge in volume in response to its <a href=\"https://seekingalpha.com/pr/17072962-catabasis-pharmaceuticals-reports-edasalonexent-preserved-muscle-function-substantially\" target=\"_blank\">announcement </a>of positive results from the extension portion of a Phase 2 clinical trial, MoveDMD, assessing edasalonexent in boys with Duchenne muscular dystrophy &#40;DMD&#41;.</li><li>Consistent improvements in all assessments of muscle function were observed after more than a year of treatment compared to the rate of change in the pre-specified control period. Significant longer-term reductions in muscle enzymes and C-reactive protein were also noted.</li><li>The data will be presented on Saturday, February 17, at the XVI International Conference on Duchenne and Becker Muscular Dystrophy in Rome.</li><li>Selected DMD-related tickers: (<a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a> <font color='red'>-0.6%</font>)(<a href='https://seekingalpha.com/symbol/SMMT' title='Summit Therapeutics'>SMMT</a> <font color='green'>+2.6%</font>)(<a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a> <font color='green'>+2.8%</font>)(<a href='https://seekingalpha.com/symbol/SLDB' title='Solid Biosciences, Inc.'>SLDB</a> <font color='green'>+0.2%</font>)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3299227-catabasis-pharmas-edasalonexent-shows-long-term-treatment-effect-mid-stage-dmd-study-shares\" target=\"_blank\">Catabasis Pharma's edasalonexent shows long-term treatment effect in mid-stage DMD study; shares ahead 59% premarket</a> (Oct. 4, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3330564\" data-linked=\"Catabasis Pharma&#39;s edasalonexent shows positive effect in mid-stage DMD study; shares up 62%\" data-tweet=\"$CATB $CATB $SRPT - Catabasis Pharma&#39;s edasalonexent shows positive effect in mid-stage DMD study; shares up 62% https://seekingalpha.com/news/3330564-catabasis-pharmas-edasalonexent-shows-positive-effect-in-mid-stage-dmd-study-shares-up-62?source=tweet\" data-url=\"https://seekingalpha.com/news/3330564-catabasis-pharmas-edasalonexent-shows-positive-effect-in-mid-stage-dmd-study-shares-up-62\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330562\" data-ts=\"1518533412\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTIE\" target=\"_blank\">PTIE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330562-pain-therapeutics-refiles-u-s-marketing-application-for-remoxy-er-shares-up-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pain Therapeutics refiles U.S. marketing application for Remoxy ER; shares up 3%</a></h4><ul><li>Pain Therapeutics (<a href='https://seekingalpha.com/symbol/PTIE' title='Pain Therapeutics'>PTIE</a> <font color='green'>+2.7%</font>) has <a href=\"https://seekingalpha.com/pr/17072922-pain-therapeutics-resubmits-new-drug-application-remoxy-er-abuse-deterrent-extended-release\" target=\"_blank\">resubmitted </a>its marketing application to the FDA seeking approval for REMOXY ER (oxycodone extended-release). The company received a CRL in September 2016 citing the need for additional clinical data.&nbsp;It expects a six-month review cycle.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3318919-pain-therapeutics-resubmit-remoxy-nda-next-quarter-shares-3-percent\" target=\"_blank\">Pain Therapeutics to resubmit Remoxy NDA next quarter; shares up 3%</a> (Dec. 18, 2017)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3210703-fda-rejects-pain-therapeutics-remoxy-er-marketing-application-shares-plummet-67-percent\" target=\"_blank\">FDA rejects Pain Therapeutics' Remoxy ER marketing application; shares plummet 67% premarket</a> (Sept. 26, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3330562\" data-linked=\"Pain Therapeutics refiles U.S. marketing application for Remoxy ER; shares up 3%\" data-tweet=\"$PTIE $SAVA - Pain Therapeutics refiles U.S. marketing application for Remoxy ER; shares up 3% https://seekingalpha.com/news/3330562-pain-therapeutics-refiles-u-s-marketing-application-for-remoxy-er-shares-up-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3330562-pain-therapeutics-refiles-u-s-marketing-application-for-remoxy-er-shares-up-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330561\" data-ts=\"1518533357\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HMNY\" target=\"_blank\">HMNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330561-helios-and-matheson-dives-after-pricing-unit-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Helios and Matheson dives after pricing unit offering</a></h4><ul> <li>Helios and Matheson Analytics (NASDAQ:<a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a>) is <font color='red'>down 30%</font> in early trading after <a href=\"https://seekingalpha.com/pr/17073056-helios-matheson-analytics-announces-pricing-105-million-public-offering\" target=\"_blank\">pricing</a> a $105M unit offering at $5.50 per unit.</li><li>Under the terms of the offering, each series A-1 unit consists of one share of Helio and one warrant to purchase an additional share.</li> <li>In the filing, Helios says it may use the proceeds to increase its ownership stake in MoviePass or to support the operations of MoviePass and MoviePass Ventures. The company can also use the funds to satisfy a portion or all of the amounts payable in connection with previously issued convertible notes and for general corporate purposes and transaction expenses. Helios may also use the proceeds to make other acquisitions.</li><li>Wild swings on HMNY are nothing new of course. Shares have traded in range of $2.20 to $38.86 over the last 52 weeks.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3330561\" data-linked=\"Helios and Matheson dives after pricing unit offering\" data-tweet=\"$HMNY - Helios and Matheson dives after pricing unit offering https://seekingalpha.com/news/3330561-helios-and-matheson-dives-after-pricing-unit-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3330561-helios-and-matheson-dives-after-pricing-unit-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>132&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330553\" data-ts=\"1518532695\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PDCO\" target=\"_blank\">PDCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330553-patterson-cos-to-vigorously-defend-against-ftc-allegations-of-anti-competitive-behavior\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Patterson Cos. to &quot;vigorously&quot; defend against FTC allegations of anti-competitive behavior</a></h4><ul><li>In a <a href=\"https://seekingalpha.com/pr/17073362-patterson-companies-denies-allegations-contained-ftc-administrative-complaint\" target=\"_blank\">statement</a>, dental products distributor Patterson Companies (<a href='https://seekingalpha.com/symbol/PDCO' title='Patterson Companies Inc.'>PDCO</a> <font color='red'>-9.2%</font>) says it intends to \"defend itself vigorously\" regarding charges by the U.S. Federal Trade Commission that it colluded with competitors not to sell to certain buying groups.</li><li>The company adds that it does not expect the matter to have a material effect on its financial condition or operating results.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3330526-schein-takes-issue-anti-trust-allegations\" target=\"_blank\">Schein takes issue with anti-trust allegations</a> (Feb. 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3330553\" data-linked=\"Patterson Cos. to &quot;vigorously&quot; defend against FTC allegations of anti-competitive behavior\" data-tweet=\"$PDCO - Patterson Cos. to &quot;vigorously&quot; defend against FTC allegations of anti-competitive behavior https://seekingalpha.com/news/3330553-patterson-cos-to-vigorously-defend-against-ftc-allegations-of-anti-competitive-behavior?source=tweet\" data-url=\"https://seekingalpha.com/news/3330553-patterson-cos-to-vigorously-defend-against-ftc-allegations-of-anti-competitive-behavior\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:38 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330548\" data-ts=\"1518532460\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SINA\" target=\"_blank\">SINA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330548-sinaplus-4-quarterly-profits-grow-25\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sina +4% as quarterly profits grow by 25%</a></h4><ul>   <li>Sina (NASDAQ:<a href='https://seekingalpha.com/symbol/SINA' title='Sina Corporation'>SINA</a>) is <font color='green'>up 4%</font> out of the market open, after <a href=\"https://seekingalpha.com/news/3330390-sinas-profit-sales-beat-significant-revenue-growth\" target=\"_blank\">Q4 earnings</a> that beat expectations with a boost from another <a href=\"https://seekingalpha.com/news/3330543-weibo-plus-4_5-percent-easy-beat-profits-triple\" target=\"_blank\">great quarter</a> at subsidiary Weibo (NASDAQ:<a href='https://seekingalpha.com/symbol/WB' title='Weibo Corporation'>WB</a>).</li>    <li>Weibo continued momentum \"on the back of sustainable user growth and engagement,\" says Sina CEO Charles Chao, and Sina's media business \"returned to the growth trajectory in 2017 ... through improvement in content offering and effective channel marketing, Sina mobile media properties continuously expanded user scale, and improved user engagement and elevated monetization capability.\"</li>    <li>Gross margin was 75% vs. a year-ago 70%; advertising gross margin was 76% vs. a year-ago 72%.</li>    <li>Revenue breakout: Advertising, $424.8M (up 57.6%); non-advertising, $79M (up 80%).</li>    <li><a href=\"https://seekingalpha.com/pr/17072635-sina-reports-fourth-quarter-fiscal-year-2017-unaudited-financial-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3330548\" data-linked=\"Sina +4% as quarterly profits grow by 25%\" data-tweet=\"$SINA $SINA $WB - Sina +4% as quarterly profits grow by 25% https://seekingalpha.com/news/3330548-sinaplus-4-quarterly-profits-grow-25?source=tweet\" data-url=\"https://seekingalpha.com/news/3330548-sinaplus-4-quarterly-profits-grow-25\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330545\" data-ts=\"1518532112\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DARE\" target=\"_blank\">DARE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330545-dar-bioscience-prices-equity-offering-shares-down-35-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Daré Bioscience prices equity offering; shares down 35% premarket</a></h4><ul><li>Dar&eacute; Bioscience (NASDAQ:<a href='https://seekingalpha.com/symbol/DARE' title='Dare Bioscience, Inc.'>DARE</a>) slumps&nbsp;<font color='red'>35%&nbsp;</font>premarket on increased volume in response to its 5M-share <a href=\"https://seekingalpha.com/pr/17073352-dare-bioscience-inc-raise-approximately-10_25-million\" target=\"_blank\">stock offering</a>. Each share will be sold with an accompanying five-year warrant to purchase 0.70 of a share of common at $3.00.</li><li>Net proceeds should be ~$9.4M so gross proceeds will be ~$10.25M implying an offer price per share of $2.05 (actual offer price is not disclosed).</li><li>Yesterday's close was $2.79.</li></ul><div class=\"tiny-share-widget\" data-id=\"3330545\" data-linked=\"Daré Bioscience prices equity offering; shares down 35% premarket\" data-tweet=\"$DARE - Daré Bioscience prices equity offering; shares down 35% premarket https://seekingalpha.com/news/3330545-dar-bioscience-prices-equity-offering-shares-down-35-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3330545-dar-bioscience-prices-equity-offering-shares-down-35-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330543\" data-ts=\"1518531915\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WB\" target=\"_blank\">WB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330543-weiboplus-4_5-after-easy-beat-profits-triple\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Weibo +4.5% after easy beat as profits triple</a></h4><ul>   <li>Weibo (NASDAQ:<a href='https://seekingalpha.com/symbol/WB' title='Weibo Corporation'>WB</a>) is <font color='green'>up 4.5%</font> premarket after posting <a href=\"https://seekingalpha.com/news/3330391-weibo-higher-3_1-percent-strong-q4-earnings-revenue-beats-guidance\" target=\"_blank\">Q4 earnings</a> that again topped estimates on top and bottom lines with revenues up sharply.</li>    <li>Advertising and marketing revenues rose 77%, and those from small and medium-sized enterprises were up 80% to $294M. Net income jumped to $131M from $43M.</li>    <li>Monthly active users rose to 392M after net adds of 79M users Y/Y; mobile MAUs were 93% of the total.</li>    <li>Average daily active users had net adds of about 33M Y/Y to hit 172M.</li>    <li>Revenue breakout: Advertising and marketing, $332.3M (up 77%); value-added service, $45.1M (up 81.4%).</li>    <li>It's guiding to Q1 revenues of $335M-$345M, well above consensus for $303.1M.</li>    <li><a href=\"https://seekingalpha.com/pr/17072629-weibo-reports-fourth-quarter-fiscal-year-2017-unaudited-financial-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3330543\" data-linked=\"Weibo +4.5% after easy beat as profits triple\" data-tweet=\"$WB - Weibo +4.5% after easy beat as profits triple https://seekingalpha.com/news/3330543-weiboplus-4_5-after-easy-beat-profits-triple?source=tweet\" data-url=\"https://seekingalpha.com/news/3330543-weiboplus-4_5-after-easy-beat-profits-triple\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330541\" data-ts=\"1518531881\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GNC\" target=\"_blank\">GNC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330541-premarket-gainers-of-9-05-02-13-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am (02/13/2018)</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/GNC' title='GNC Holdings, Inc.'>GNC</a> <font color='green'>+40%</font>&nbsp;on Q4 <a href=\"https://seekingalpha.com/news/3330407-gnc-holdings-eps-line-misses-revenue\" target=\"_blank\">result</a>.</li>     <li><a href='https://seekingalpha.com/symbol/CATB' title='Catabasis Pharmaceuticals'>CATB</a> <font color='green'>+31%</font>&nbsp;on new <a href=\"https://seekingalpha.com/pr/17072962-catabasis-pharmaceuticals-reports-edasalonexent-preserved-muscle-function-substantially\" target=\"_blank\">positive</a> efficacy and safety results showing preservation of muscle function and sustained disease-modifying effects in boys with Duchene muscular dystrophy in the MoveDMD trial open-label extension following 48 and 60 weeks of treatment with edasalonexent.</li>     <li><a href='https://seekingalpha.com/symbol/ABC' title='AmerisourceBergen Corporation'>ABC</a> <font color='green'>+13%</font>&nbsp;on potential interest by Walgreens&nbsp;(NASDAQ:<a href='https://seekingalpha.com/symbol/WBA' title='Walgreens Boots Alliance, Inc.'>WBA</a>).</li>     <li><a href='https://seekingalpha.com/symbol/KDMN' title='Kadmon Holdings'>KDMN</a> <font color='green'>+12%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/UAA' title='Under Armour, Inc.'>UAA</a> <font color='green'>+10%</font>&nbsp;on Q4 <a href=\"https://seekingalpha.com/news/3330434-armour-eps-line-beats-revenue\" target=\"_blank\">result</a>.</li>     <li><a href='https://seekingalpha.com/symbol/CBAY' title='CymaBay Therapeutics'>CBAY</a> <font color='green'>+10%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3330516-premarket-analyst-action-healthcare\" target=\"_blank\">positive</a> analyst action.</li>     <li>COGT <font color='green'>+8%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/HDNG' title='Hardinge, Inc.'>HDNG</a> <font color='green'>+8%</font>&nbsp;<a href=\"https://seekingalpha.com/news/3330371-hardinge-go-private-245m-shares-plus-6_2-percent\" target=\"_blank\">going private</a> for 245M.</li>     <li><a href='https://seekingalpha.com/symbol/ADXS' title='Advaxis Inc.'>ADXS</a> <font color='green'>+8%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17073068-advaxis-submits-conditional-marketing-authorization-application-axalimogene-filolisbac-second\" target=\"_blank\">submitting</a> a conditional Marketing Authorization Application to the European Medicines Agency for the company&rsquo;s lead Lm Technology product candidate.</li>     <li><a href='https://seekingalpha.com/symbol/APRN' title='Blue Apron Holdings, Inc.'>APRN</a> <font color='green'>+7%</font>&nbsp;on smaller-than-expected EBITDA <a href=\"https://seekingalpha.com/news/3330472-blue-apron-flies-posting-smaller-expected-ebitda-loss\" target=\"_blank\">loss</a>.</li>     <li><a href='https://seekingalpha.com/symbol/UA' title='Under Armour, Inc. Class C'>UA</a> <font color='green'>+9%</font>&nbsp;on Q4&nbsp;<a href=\"https://seekingalpha.com/news/3330434-armour-eps-line-beats-revenue\" target=\"_blank\">result</a>.</li>     <li><a href='https://seekingalpha.com/symbol/DCIX' title='Diana Containerships Inc.'>DCIX</a> <font color='green'>+6%</font>&nbsp;on the <a href=\"https://seekingalpha.com/pr/17073317-diana-containerships-inc-announces-sale-panamax-container-vessel-m-v-new-jersey\" target=\"_blank\">sale</a>&nbsp;of a panamax container vessel.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3330541\" data-linked=\"Premarket Gainers as of 9:05 am (02/13/2018)\" data-tweet=\"$GNC $GNC $CATB - Premarket Gainers as of 9:05 am (02/13/2018) https://seekingalpha.com/news/3330541-premarket-gainers-of-9-05-02-13-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3330541-premarket-gainers-of-9-05-02-13-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330540\" data-ts=\"1518531627\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PACB\" target=\"_blank\">PACB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330540-pacific-bio-prices-stock-offering-2_40-shares-down-17-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pacific Bio prices stock offering at $2.40; shares down 17% premarket</a></h4><ul><li>Pacific Biosciences of California (NASDAQ:<a href='https://seekingalpha.com/symbol/PACB' title='Pacific Biosciences of California'>PACB</a>) <a href=\"https://seekingalpha.com/pr/17073297-pacific-biosciences-california-inc-announces-pricing-public-offering-common-stock\" target=\"_blank\">prices </a>its public offering of 12.5M shares of common stock at $2.40 per share. Underwriters over-allotment is an additional 1.875M shares. Closing date is February 15.</li><li>Yesterday's close was $2.54. Shares are down&nbsp;<font color='red'>17%</font>&nbsp;premarket on average volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3330540\" data-linked=\"Pacific Bio prices stock offering at $2.40; shares down 17% premarket\" data-tweet=\"$PACB - Pacific Bio prices stock offering at $2.40; shares down 17% premarket https://seekingalpha.com/news/3330540-pacific-bio-prices-stock-offering-2_40-shares-down-17-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3330540-pacific-bio-prices-stock-offering-2_40-shares-down-17-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330537\" data-ts=\"1518531450\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DARE\" target=\"_blank\">DARE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330537-premarket-losers-of-9-05-2-13-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am (2/13/2018)</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/DARE' title='Dare Bioscience, Inc.'>DARE</a>&nbsp;<font color='red'>-33%</font>&nbsp;on&nbsp;<a href=\"https://seekingalpha.com/news/3330465-dare-bioscience-announces-public-offering-common-stock\" target=\"_blank\">announcing</a> public offering of common stock.</li><li><a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='red'>-29%</font>.</li><li><a href='https://seekingalpha.com/symbol/PACB' title='Pacific Biosciences of California'>PACB</a>&nbsp;<font color='red'>-14%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3330285-pacific-biosciences-launches-stock-offering\" target=\"_blank\">launching</a> stock offering.</li><li><a href='https://seekingalpha.com/symbol/AFMD' title='Affimed Therapeutics'>AFMD</a>&nbsp;<font color='red'>-12%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3330414-affimed-prices-stock-offering-2_00\" target=\"_blank\">pricing</a> stock offering.</li><li><a href='https://seekingalpha.com/symbol/PDCO' title='Patterson Companies Inc.'>PDCO</a>&nbsp;<font color='red'>-9%</font>&nbsp;after The Federal Trade Commission&nbsp;filing a <a href=\"https://seekingalpha.com/news/3330367-ftc-alleges-dental-supply-companies-conspired-refuse-discounts\" target=\"_blank\">complaint</a> for violating U.S. antitrust laws.</li><li><a href='https://seekingalpha.com/symbol/HSIC' title='Henry Schein, Inc.'>HSIC</a>&nbsp;<font color='red'>-9%</font>&nbsp;after The Federal Trade Commission&nbsp;filing a&nbsp;<a href=\"https://seekingalpha.com/news/3330526-schein-takes-issue-anti-trust-allegations\" target=\"_blank\">complaint</a>&nbsp;for violating U.S. antitrust laws.</li><li><a href='https://seekingalpha.com/symbol/EMAN' title='eMagin Corporation'>EMAN</a>&nbsp;<font color='red'>-7%</font>&nbsp;on proving <a href=\"https://seekingalpha.com/pr/17072310-emagin-corporation-updates-market\" target=\"_blank\">update</a> on&nbsp;consumer electronics&nbsp;companies' participation in the offering.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3330537\" data-linked=\"Premarket Losers as of 9:05 am (2/13/2018)\" data-tweet=\"$DARE $DARE $HMNY - Premarket Losers as of 9:05 am (2/13/2018) https://seekingalpha.com/news/3330537-premarket-losers-of-9-05-2-13-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3330537-premarket-losers-of-9-05-2-13-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330536\" data-ts=\"1518531425\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIT\" target=\"_blank\">FIT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330536-fitbit-will-acquire-connected-health-platform-sharesminus-1_1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fitbit will acquire connected health platform; shares -1.1%</a></h4><ul><li>        Fitbit (NYSE:<a href='https://seekingalpha.com/symbol/FIT' title='Fitbit, Inc.'>FIT</a>) will <a href=\"https://seekingalpha.com/pr/17073267-fitbit-inc-acquire-twine-health\" target=\"_blank\">acquire</a> HIPAA-compliant connected health platform Twine Health for undisclosed terms.</li><li>               The Twine Health platform claims to &ldquo;help people manage chronic conditions, such as diabetes and hypertension, and aid in lifestyle interventions, such as weight loss and smoking cessation, by making it easy for care teams of providers, coaches, friends, and family to collaborate on care plans.&rdquo;&nbsp;</li><li>               The acquisition is expected to close in Q1. As part of the deal, the Twine Health team will join Fitbit&rsquo;s Health Solutions group, and founder and CEO Dr. John Moore will serve as Fitbit&rsquo;s Medical Director. &nbsp;&nbsp;</li><li>               Fitbit shares are&nbsp;<font color='red'>down 1.1%</font>&nbsp;premarket.&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3330536\" data-linked=\"Fitbit will acquire connected health platform; shares -1.1%\" data-tweet=\"$FIT - Fitbit will acquire connected health platform; shares -1.1% https://seekingalpha.com/news/3330536-fitbit-will-acquire-connected-health-platform-sharesminus-1_1?source=tweet\" data-url=\"https://seekingalpha.com/news/3330536-fitbit-will-acquire-connected-health-platform-sharesminus-1_1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>131&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330535\" data-ts=\"1518531386\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBIO\" target=\"_blank\">CBIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330535-catalyst-bio-prices-stock-offering-34-shares-down-2-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Catalyst Bio prices stock offering at $34; shares down 2% premarket</a></h4><ul><li>Catalyst Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/CBIO' title='Catalyst Biosciences, Inc.'>CBIO</a>) slips&nbsp;<font color='red'>2%</font>&nbsp;premarket on increased volume in response to its <a href=\"https://seekingalpha.com/pr/17073137-catalyst-biosciences-announces-pricing-public-offering-common-stock\" target=\"_blank\">public offering</a> of 2,941,176 shares of common stock at $34 per share. Underwriters over-allotment is an additional 441,176 shares. Closing date is February 15.</li><li>Yesterday's close was $35.60.</li></ul><div class=\"tiny-share-widget\" data-id=\"3330535\" data-linked=\"Catalyst Bio prices stock offering at $34; shares down 2% premarket\" data-tweet=\"$CBIO - Catalyst Bio prices stock offering at $34; shares down 2% premarket https://seekingalpha.com/news/3330535-catalyst-bio-prices-stock-offering-34-shares-down-2-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3330535-catalyst-bio-prices-stock-offering-34-shares-down-2-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330534\" data-ts=\"1518531095\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WBA\" target=\"_blank\">WBA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330534-wba-takeout-of-amerisourcebergen-boost-non-gaap-eps-10-mizuho\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WBA takeout of AmerisourceBergen could boost non-GAAP EPS 10% - Mizuho</a></h4><ul><li>In a note, Mizuho sasy Walgreens Boots Alliance's (NASDAQ:<a href='https://seekingalpha.com/symbol/WBA' title='Walgreens Boots Alliance, Inc.'>WBA</a>) reported interest in fully acquiring AmerisourceBergen (NYSE:<a href='https://seekingalpha.com/symbol/ABC' title='AmerisourceBergen Corporation'>ABC</a>) should not be a surprise considering their close relationship. The companies formed a drug purchasing partnership in 2013 that resulted in WBA being ABC's largest customer representing ~26% of its revenues. WBA also owns ~26% of ABC and has a board seat.</li><li>Assuming a 16.3x forward P/E multiple and the high end of ABC's 2018 guidance, the acquisition price could as high as $107 - 109 per share. A tie-up could add 10% to WBA's fiscal 2018 non-GAAP EPS estimate of $5.93.</li><li>Premarket: WBA down&nbsp;<font color='red'>1%</font>, ABC up&nbsp;<font color='green'>12%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3330534\" data-linked=\"WBA takeout of AmerisourceBergen could boost non-GAAP EPS 10% - Mizuho\" data-tweet=\"$WBA $WBA $ABC - WBA takeout of AmerisourceBergen could boost non-GAAP EPS 10% - Mizuho https://seekingalpha.com/news/3330534-wba-takeout-of-amerisourcebergen-boost-non-gaap-eps-10-mizuho?source=tweet\" data-url=\"https://seekingalpha.com/news/3330534-wba-takeout-of-amerisourcebergen-boost-non-gaap-eps-10-mizuho\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330526\" data-ts=\"1518530406\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HSIC\" target=\"_blank\">HSIC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330526-schein-takes-issue-anti-trust-allegations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Schein takes issue with anti-trust allegations</a></h4><ul><li>Medical products distributor Henry Schein (NASDAQ:<a href='https://seekingalpha.com/symbol/HSIC' title='Henry Schein, Inc.'>HSIC</a>) disagrees with allegations from the U.S. Federal Trade Commission that it engaged in anti-competitive behavior related to discounts to buying groups for dental supplies.</li><li>In a <a href=\"https://seekingalpha.com/pr/17072716-henry-schein-denies-ftc-anti-trust-allegations\" target=\"_blank\">statement</a>, the company says, \"Based on the FTC's press release, the Company is being accused of participating in a conspiracy to refuse to provide discounts to, or compete for, the business of buying groups. Contrary to the FTC's allegations, the Company was a leader in supplying buying groups, has consistently done business with buying groups, has a dedicated team to serve buying groups, and never entered into an agreement with others to refuse to do business with buying groups. Based on the FTC's original definition of buying groups, the Company does business with more than 100 buying groups. Even under a narrower definition recently advanced by the FTC, the Company has done business, and continues to do business, with the very groups it is now accused of boycotting. The Company believes that the allegations as described in the press release are meritless and intends to defend itself vigorously. The Company does not anticipate that this matter will have a material adverse effect on our financial condition or results of operations.\"</li><li>Shares are down&nbsp;<font color='red'>7%</font>&nbsp;premarket on light volume.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3330367-ftc-alleges-dental-supply-companies-conspired-refuse-discounts\" target=\"_blank\">FTC alleges dental supply companies conspired to refuse discounts</a> (Feb. 12)</li></ul><div class=\"tiny-share-widget\" data-id=\"3330526\" data-linked=\"Schein takes issue with anti-trust allegations\" data-tweet=\"$HSIC - Schein takes issue with anti-trust allegations https://seekingalpha.com/news/3330526-schein-takes-issue-anti-trust-allegations?source=tweet\" data-url=\"https://seekingalpha.com/news/3330526-schein-takes-issue-anti-trust-allegations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330514\" data-ts=\"1518529366\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DAN\" target=\"_blank\">DAN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330514-dana-holding-beat-estimates-in-q4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dana Holding beat the estimates in Q4</a></h4><ul>     <li>Dana Holding (NYSE:<a href='https://seekingalpha.com/symbol/DAN' title='Dana, Inc.'>DAN</a>)&nbsp;reports revenue rose 27% in <a href=\"https://seekingalpha.com/pr/17072736-dana-incorporated-announces-strong-2017-financial-results-affirms-significant-2018-guidance\" target=\"_blank\">Q4</a>, primarily&nbsp;due&nbsp;to higher end-market demand in all business units, conversion of sales backlog, and favorable currency.</li>     <li>Revenue by segment:&nbsp;Light Vehicle: $803M (+15.7%);&nbsp;Commercial Vehicle: $355M&nbsp;(+27.7%);&nbsp;Off-Highway: $414M (+90.8%);&nbsp;Power Technologies: $265M (+2.7%)</li>     <li>Gross margin rate down 30 bps to 13.8%.</li>     <li>SG&amp;A expense rate up 10 bps to 7.2%.</li>     <li>Adjusted EBITDA expanded 18.7% to $197M.</li>     <li><b>FY2018 Guidance</b>: Sales: $7.5B to $7.7B; Adjusted EBITDA: $910M to $960M; Adjusted EBITDA margin: ~12.3%; Adjusted EPS: ~$2.60 to $2.90; Capital expenditure: ~4% of sales; Free cash flow: ~3.5% of sales.</li>           </ul><div class=\"tiny-share-widget\" data-id=\"3330514\" data-linked=\"Dana Holding beat the estimates in Q4\" data-tweet=\"$DAN - Dana Holding beat the estimates in Q4 https://seekingalpha.com/news/3330514-dana-holding-beat-estimates-in-q4?source=tweet\" data-url=\"https://seekingalpha.com/news/3330514-dana-holding-beat-estimates-in-q4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:42 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330508\" data-ts=\"1518528243\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DNR\" target=\"_blank\">DNR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330508-denbury-resources-says-q4-production-inched-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Denbury Resources says Q4 production inched higher</a></h4><ul>     <li>Denbury Resources (NYSE:<a href='https://seekingalpha.com/symbol/DNR' title='Denbury Resources Inc.'>DNR</a>) <font color='green'>+2.9%</font> premarket after an <a href=\"https://seekingalpha.com/pr/17072489-denbury-provides-operational-update-results-successful-mission-canyon-exploitation-well-2018\" target=\"_blank\">operational update</a> shows Q4 production surpassing 61K boe/day, up 1% Q/Q and in-line with expectations, and FY 2017 production falling 4% Y/Y to 60,298 boe/day.</li>     <li>DNR says year-end 2017 proved reserves totaled 260M boe, a 127% replacement of annual production, and year-end preliminary PV-10 value was $2.5B, up from $1.5B at year-end 2016</li>     <li>DNR anticipates 2018 development capex of $300M-$325M after spending $241M in 2017, with production estimated at 60K-64K boe/day.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3330508\" data-linked=\"Denbury Resources says Q4 production inched higher\" data-tweet=\"$DNR - Denbury Resources says Q4 production inched higher https://seekingalpha.com/news/3330508-denbury-resources-says-q4-production-inched-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/3330508-denbury-resources-says-q4-production-inched-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330506\" data-ts=\"1518528142\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADT\" target=\"_blank\">ADT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330506-analysts-launch-positive-coverage-on-adt\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analysts launch positive coverage on ADT</a></h4><ul> <li>Analysts launch on ADT (NYSE:<a href='https://seekingalpha.com/symbol/ADT' title='The ADT Corporation'>ADT</a>) with a rush of positive ratings.</li> <li>Morgan Stanley calls ADT the argest company in a growing, recession-resilient industry as it starts it off at Overweight with a $19 price target.</li> <li>Buy or buy-equivalent ratings are also in from Bank of America Merrill Lynch, Citi, Deutsche Bank, Goldman Sachs and RBC.</li><li>A list of the underwriters on the ADT IPO is <a href=\"https://www.nasdaq.com/markets/ipos/company/adt-inc-1020407-85664?tab=experts\" target=\"_blank\">here</a>.</li> <li>Sources: Nasdaq.com, Bloomberg.</li><li>ADT <font color='green'>+2.92%</font> premarket to $13.05. The company priced its IPO at $14 last month.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3330506\" data-linked=\"Analysts launch positive coverage on ADT\" data-tweet=\"$ADT - Analysts launch positive coverage on ADT https://seekingalpha.com/news/3330506-analysts-launch-positive-coverage-on-adt?source=tweet\" data-url=\"https://seekingalpha.com/news/3330506-analysts-launch-positive-coverage-on-adt\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330502\" data-ts=\"1518527913\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GNC\" target=\"_blank\">GNC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330502-gnc-and-harbin-pharmaceutical-announce-300m-strategic-investment-and-china-joint-venture\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GNC and Harbin Pharmaceutical announce $300M strategic investment and China joint venture</a></h4><ul><li>GNC Holdings (NYSE:<a href='https://seekingalpha.com/symbol/GNC' title='GNC Holdings, Inc.'>GNC</a>) <a href=\"https://seekingalpha.com/pr/17072682-gnc-harbin-pharmaceutical-announce-300-million-strategic-investment-china-joint-venture\" target=\"_blank\">signs</a> an agreement regarding a strategic partnership and China joint venture agreement with Harbin Pharmaceutical Group (\"Hayao\"), a leading pharmaceutical company in China.</li><li>Under the terms of the agreement, Hayao will invest ~$300M in GNC in the form of newly issued convertible perpetual preferred shares with a conversion price of $5.35 and a 6.5% annual coupon payable in cash or in kind.</li><li>Closing date is expected in H2 2018.&nbsp;Following the closing, Hayao will own ~40% of GNC on an as converted basis.</li><li>In addition, GNC and Hayao will form a joint venture for the manufacturing, marketing, sale and distribution of GNC-branded products in China.</li> <li>GNC will also amend certain terms and extend the maturity date by two years of its existing term loan facility due March 2019. The Company's existing Revolving Credit Facility will be cancelled and GNC will enter into a New $100M ABL Revolver.</li><li>The Company will also issue a $275M ABL Term Loan as part of the maturity extension.</li><li>Shares of GNC are up&nbsp;<font color='green'>37%</font>&nbsp;premarket on higher volume.</li>       </ul><div class=\"tiny-share-widget\" data-id=\"3330502\" data-linked=\"GNC and Harbin Pharmaceutical announce $300M strategic investment and China joint venture\" data-tweet=\"$GNC - GNC and Harbin Pharmaceutical announce $300M strategic investment and China joint venture https://seekingalpha.com/news/3330502-gnc-and-harbin-pharmaceutical-announce-300m-strategic-investment-and-china-joint-venture?source=tweet\" data-url=\"https://seekingalpha.com/news/3330502-gnc-and-harbin-pharmaceutical-announce-300m-strategic-investment-and-china-joint-venture\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>48&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330493\" data-ts=\"1518527118\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ONDK\" target=\"_blank\">ONDK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330493-ondeck-capital-up-1-after-earnings-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">OnDeck Capital up 1% after earnings beat</a></h4><ul><li>Q4 adjusted net income of $8.1M or $0.10 per share vs. loss of $31.4M and $0.44 per share a year ago. Adjusted EBITDA of $9.7M.</li><li>UPB dipped 0.5% during quarter to $936M; UPB is expected to being growing again in Q1.</li><li>Q1 revenue guidance of $86M-$90M, with adjusted net income of $1M-$5M. Full-year revenue guidance of $370M-$382M, with adjusted net income of $16M-$28M.</li><li><a href=\"https://investors.ondeck.com\" target=\"_blank\">Conference call</a> is just underway.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3330438-ondeck-capital-beats-0_06-beats-revenue\" target=\"_blank\">OnDeck Capital beats by $0.06, beats on revenue</a> (Feb. 13)</li><li><a href='https://seekingalpha.com/symbol/ONDK' title='OnDeck Capital'>ONDK</a>&nbsp;<font color='green'>+1.1%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3330493\" data-linked=\"OnDeck Capital up 1% after earnings beat\" data-tweet=\"$ONDK - OnDeck Capital up 1% after earnings beat https://seekingalpha.com/news/3330493-ondeck-capital-up-1-after-earnings-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3330493-ondeck-capital-up-1-after-earnings-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:05 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330485\" data-ts=\"1518526985\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLLS\" target=\"_blank\">CLLS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330485-two-u-s-patents-granted-to-cellectis-for-crispr-use-in-t-cells\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Two U.S. patents granted to Cellectis for CRISPR use in T-Cells</a></h4><ul><li>Cellectis&nbsp;(NASDAQ:<a href='https://seekingalpha.com/symbol/CLLS' title='Cellectis S.A.'>CLLS</a>) <a href=\"https://seekingalpha.com/pr/17072578-two-issued-u-s-patents-granted-cellectis-crispr-use-t-cells\" target=\"_blank\">announces</a> the issuance of two U.S. patents -       US 9,855,297 and US 9,890,393 - for the invention of certain uses of       RNA-guided endonucleases, such as Cas9 or Cpf1, for the genetic       engineering of T-cells. The patents came into force on January 2<sup>&nbsp;</sup>and February 13, respectively.</li>     <li>Both patents claim methods by which T-cells are gene edited using       transient expression of CRISPR/Cas9 components.</li><li>Shares are up&nbsp;<font color='green'>2%</font>&nbsp;premarket on light volume.</li>               </ul><div class=\"tiny-share-widget\" data-id=\"3330485\" data-linked=\"Two U.S. patents granted to Cellectis for CRISPR use in T-Cells\" data-tweet=\"$CLLS - Two U.S. patents granted to Cellectis for CRISPR use in T-Cells https://seekingalpha.com/news/3330485-two-u-s-patents-granted-to-cellectis-for-crispr-use-in-t-cells?source=tweet\" data-url=\"https://seekingalpha.com/news/3330485-two-u-s-patents-granted-to-cellectis-for-crispr-use-in-t-cells\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330484\" data-ts=\"1518526872\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GNRC\" target=\"_blank\">GNRC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330484-on-generacs-q4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Generac&#39;s Q4</a></h4><ul><li>Generac (NYSE:<a href='https://seekingalpha.com/symbol/GNRC' title='Generac Holdings Inc.'>GNRC</a>)&nbsp;reports domestic sales rose 11.2% to $377.9M in <a href=\"https://seekingalpha.com/pr/17072691-generac-reports-fourth-quarter-full-year-2017-results\" target=\"_blank\">Q4</a>.</li><li>International sales grew 41.8% to $110.2M, primarily due to the contribution from the recent acquisition of Motortech.</li><li>Residential product sales up 11.2% to $265.52M and&nbsp;Commercial &amp; Industrial product sales advanced 27.1% to $188.32M.</li><li>Gross margin rate -10 bps to 36.8%.</li><li>Operating margin rate improved 80 bps to 19.3%.</li><li>Adjusted EBITDA grew 21% to $111.13M.</li><li><b>FY2018 Guidance</b>: Net sales: +3% to +5%; Total organic sales: +9% to +10%; Net margin rate : 9.5% to 10%; Adjusted EBITDA margin: 19% to 19.5; Tax rate: 25% to 26%.</li></ul><div class=\"tiny-share-widget\" data-id=\"3330484\" data-linked=\"More on Generac&#39;s Q4\" data-tweet=\"$GNRC - More on Generac&#39;s Q4 https://seekingalpha.com/news/3330484-on-generacs-q4?source=tweet\" data-url=\"https://seekingalpha.com/news/3330484-on-generacs-q4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330479\" data-ts=\"1518526549\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ICHR\" target=\"_blank\">ICHR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330479-needham-upgrades-ichor-to-81-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Needham upgrades Ichor to 81% upside</a></h4><ul><li>        Needham upgrades Ichor (NASDAQ:<a href='https://seekingalpha.com/symbol/ICHR' title='Ichor Holdings, Ltd.'>ICHR</a>) from Buy to Strong Buy with a $42 price target, a nearly 81% upside to yesterday&rsquo;s close.</li><li>               Firm says the post-earnings sell-off is due to unfounded fear of Ichor&rsquo;s business peaking and that the current price already discounts anticipated EPS estimate reductions.&nbsp;</li><li>               The Street&rsquo;s current model shows no sequential growth for the next five quarters, which Needham says ignores growth drivers that will enable Ichor to deliver positive surprises in the coming quarters&nbsp;</li><li>               Source: Briefing.com.&nbsp;</li><li>               Ichor shares are&nbsp;<font color='green'>up 6.3%</font>&nbsp;premarket to $24.70 with a 52-week range of $16.40 to $35.51. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3330479\" data-linked=\"Needham upgrades Ichor to 81% upside\" data-tweet=\"$ICHR - Needham upgrades Ichor to 81% upside https://seekingalpha.com/news/3330479-needham-upgrades-ichor-to-81-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3330479-needham-upgrades-ichor-to-81-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330475\" data-ts=\"1518526288\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABC\" target=\"_blank\">ABC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330475-amerisourcebergens-gain-is-mckesson-and-cardinals-pain-in-red-on-potential-interest-in-abc\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AmerisourceBergen&#39;s gain is McKesson and Cardinal&#39;s pain, both in the red on potential interest in ABC by Walgreens</a></h4><ul><li>AmerisourceBergen (NYSE:<a href='https://seekingalpha.com/symbol/ABC' title='AmerisourceBergen Corporation'>ABC</a>) is up&nbsp;<font color='green'>14%</font>&nbsp;premarket on average volume in response to a WSJ report that Walgreens Boots Alliance (NASDAQ:<a href='https://seekingalpha.com/symbol/WBA' title='Walgreens Boots Alliance, Inc.'>WBA</a>) may be interested in acquiring the remainder of the drug wholesaler that it does not own.</li><li>Investors are turning a cold shoulder to competitors McKesson (NYSE:<a href='https://seekingalpha.com/symbol/MCK' title='McKesson Corporation'>MCK</a>) and Cardinal Health (NYSE:<a href='https://seekingalpha.com/symbol/CAH' title='Cardinal Health Inc.'>CAH</a>), down&nbsp;<font color='red'>4%</font>&nbsp;and&nbsp;<font color='red'>3%</font>, respectively, premarket, albeit both on light volume.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3330373-amerisourcebergen-plus-22-percent-report-walgreens-buyout-talk\" target=\"_blank\">AmerisourceBergen +22% on report of Walgreens buyout talk</a> (Feb. 12)</li></ul><div class=\"tiny-share-widget\" data-id=\"3330475\" data-linked=\"AmerisourceBergen&#39;s gain is McKesson and Cardinal&#39;s pain, both in the red on potential interest in ABC by Walgreens\" data-tweet=\"$ABC $ABC $WBA - AmerisourceBergen&#39;s gain is McKesson and Cardinal&#39;s pain, both in the red on potential interest in ABC by Walgreens https://seekingalpha.com/news/3330475-amerisourcebergens-gain-is-mckesson-and-cardinals-pain-in-red-on-potential-interest-in-abc?source=tweet\" data-url=\"https://seekingalpha.com/news/3330475-amerisourcebergens-gain-is-mckesson-and-cardinals-pain-in-red-on-potential-interest-in-abc\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330474\" data-ts=\"1518526235\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MMM\" target=\"_blank\">MMM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330474-3m-raised-to-buy-deutsche-bank\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">3M raised to Buy at Deutsche Bank</a></h4><ul><li>Deutsche Bank is jumping aboard the 3M (NYSE:<a href='https://seekingalpha.com/symbol/MMM' title='3M Company'>MMM</a>) train after a 26% gain for the stock over the past year.</li><li>The firm <a href=\"https://twitter.com/UPBOptionMil/status/963379921371435008\" target=\"_blank\">upgrades</a> to Buy with a $275 price target, suggesting another 20% upside. Shares <font color='green'>up 0.9%</font> premarket to $231.</li></ul><div class=\"tiny-share-widget\" data-id=\"3330474\" data-linked=\"3M raised to Buy at Deutsche Bank\" data-tweet=\"$MMM - 3M raised to Buy at Deutsche Bank https://seekingalpha.com/news/3330474-3m-raised-to-buy-deutsche-bank?source=tweet\" data-url=\"https://seekingalpha.com/news/3330474-3m-raised-to-buy-deutsche-bank\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3330473\" data-ts=\"1518525839\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3330473-med-supply-stocks-drop-amazon-preps-entry\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Med supply stocks drop as Amazon preps an entry</a></h4><ul><li>        Amazon (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) spoke with hospital executives to tailor its Amazon Business service for medical supplies, according to the <a href=\"https://www.wsj.com/articles/amazons-latest-ambition-to-be-a-major-hospital-supplier-1518517802\" target=\"_blank\">WSJ</a>.</li><li>               Amazon sent employees to a &ldquo;large Midwestern hospital system&rdquo; for a pilot program testing if officials can use Business to order health-care supplies for the system&rsquo;s 150 outpatient facilities.&nbsp;</li><li>               The program was customized for that system&rsquo;s needs to allow for price comparisons between current distributors and Amazon Business.&nbsp;</li><li>               Hospitals typically negotiate and sign contracts to buy supplies directly from manufacturers or distributors. Group-purchasing companies can also negotiate on behalf of multiple hospitals to leverage demand.&nbsp;</li><li>               Fees, administration, marketing, and shipping costs account for up to 30% of health-care supply costs, according to Citigroup Global Markets data.&nbsp;</li><li>               Healthcare distributors and group purchasers moving on the news: Cardinal Health (NYSE:<a href='https://seekingalpha.com/symbol/CAH' title='Cardinal Health Inc.'>CAH</a>)&nbsp;<font color='red'>down 3.7%</font>&nbsp;premarket, Walgreens Boots Alliance (NASDAQ:<a href='https://seekingalpha.com/symbol/WBA' title='Walgreens Boots Alliance, Inc.'>WBA</a>)&nbsp;<font color='red'>down 1.8%</font>, Owens &amp; Minor (NYSE:<a href='https://seekingalpha.com/symbol/OMI' title='Owens & Minor Inc.'>OMI</a>)&nbsp;<font color='red'>down 4.5%</font>, &nbsp;McKesson (NYSE:<a href='https://seekingalpha.com/symbol/MCK' title='McKesson Corporation'>MCK</a>)&nbsp;<font color='red'>down 4%</font>; Henry Schein&nbsp;<font color='red'>down 5.5%</font>.&nbsp;</li><li>               Amazon shares are&nbsp;<font color='red'>down 0.4%</font>. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3326320-amazon-jpmorgan-berkshire-hathaway-launching-healthcare-company\" target=\"_blank\">Amazon, JPMorgan, and Berkshire Hathaway launching a healthcare company</a> (Jan. 30)</li></ul><div class=\"tiny-share-widget\" data-id=\"3330473\" data-linked=\"Med supply stocks drop as Amazon preps an entry\" data-tweet=\"$AMZN $AMZN $CAH - Med supply stocks drop as Amazon preps an entry https://seekingalpha.com/news/3330473-med-supply-stocks-drop-amazon-preps-entry?source=tweet\" data-url=\"https://seekingalpha.com/news/3330473-med-supply-stocks-drop-amazon-preps-entry\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>65&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}